CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: hydralazine
Accession: CHEBI:5775
browse the term
Definition: The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Synonyms: related_synonym: (1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine; Formula=C8H8N4; Hydralazin; Hydrallazine; Hydrazinophthalazine; Hydrazone 1(2H)-phthalazinone; Hypophthalin; Idralazina; InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12); InChIKey=RPTUSVTUFVMDQK-UHFFFAOYSA-N; SMILES=NNc1nncc2ccccc12; hidralazina; hydralazinum; phthalazin-1-ylhydrazine
xref: Beilstein:132615; CAS:86-54-4; DrugBank:DB01275; Drug_Central:1384; Gmelin:4337; KEGG:C07040; KEGG:D08044; LINCS:LSM-15370
xref_mesh: MESH:D006830
xref: PMID:808562; Patent:US2484029; Wikipedia:Hydralazine
G
Abcb5
ATP binding cassette subfamily B member 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ABCB5 mRNA
CTD
PMID:17183730
NCBI chr 6:139,836,528...139,932,830
Ensembl chr 6:139,835,949...139,932,830
G
Acaa1a
acetyl-CoA acyltransferase 1A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAA1 mRNA
CTD
PMID:17183730
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
G
Acad9
acyl-CoA dehydrogenase family, member 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAD9 mRNA
CTD
PMID:17183730
NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547
G
Acat2
acetyl-CoA acetyltransferase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAT2 mRNA
CTD
PMID:17183730
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
G
Ace
angiotensin I converting enzyme
multiple interactions
EXP
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA]
CTD
PMID:16326922
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
G
Acin1
apoptotic chromatin condensation inducer 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ACIN1 mRNA
CTD
PMID:17183730
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
G
Acot2
acyl-CoA thioesterase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ACOT2 mRNA
CTD
PMID:17183730
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
G
Acta1
actin, alpha 1, skeletal muscle
multiple interactions
EXP
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA]
CTD
PMID:16326922
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
G
Adamts10
ADAM metallopeptidase with thrombospondin type 1 motif, 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ADAMTS10 mRNA
CTD
PMID:17183730
NCBI chr 7:14,331,659...14,361,620
Ensembl chr 7:14,331,745...14,361,620
G
Adgra3
adhesion G protein-coupled receptor A3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ADGRA3 mRNA
CTD
PMID:17183730
NCBI chr14:60,874,719...60,976,341
Ensembl chr14:60,874,715...60,976,332
G
Adipor1
adiponectin receptor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ADIPOR1 mRNA
CTD
PMID:17183730
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
G
Adsl
adenylosuccinate lyase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ADSL mRNA
CTD
PMID:17183730
NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760
G
Afg3l2
AFG3 like matrix AAA peptidase subunit 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of AFG3L2 mRNA
CTD
PMID:17183730
NCBI chr18:60,954,268...60,999,110
Ensembl chr18:60,954,268...60,999,110
G
Agk
acylglycerol kinase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of AGK mRNA
CTD
PMID:17183730
NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934
G
Agpat2
1-acylglycerol-3-phosphate O-acyltransferase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of AGPAT2 mRNA
CTD
PMID:17183730
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
G
Agt
angiotensinogen
multiple interactions decreases response to substance
EXP ISO
Hydralazine affects the reaction [AGT protein results in increased abundance of Fatty Acids, Nonesterified]; Hydralazine affects the reaction [AGT protein results in increased abundance of Triglycerides]; Hydralazine inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK1 protein]; Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK3 protein]; Hydralazine inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA] Hydralazine results in decreased susceptibility to AGT protein modified form
CTD
PMID:16344371 PMID:19109942 PMID:21289285
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
G
Akr1a1
aldo-keto reductase family 1 member A1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of AKR1A1 mRNA
CTD
PMID:17183730
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
G
Akr1c2
aldo-keto reductase family 1, member C2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of AKR1C2 mRNA
CTD
PMID:17183730
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
G
Akt2
AKT serine/threonine kinase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of AKT2 mRNA
CTD
PMID:17183730
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
G
Alb
albumin
multiple interactions affects binding
ISO
Hydralazine inhibits the reaction [[Acrolein binds to ALB protein] which results in increased expression of HMOX1 mRNA] Hydralazine binds to [Acrolein binds to ALB protein]
CTD
PMID:32530271
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
G
Aldh18a1
aldehyde dehydrogenase 18 family, member A1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ALDH18A1 mRNA
CTD
PMID:17183730
NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
G
Aldh9a1
aldehyde dehydrogenase 9 family, member A1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ALDH9A1 mRNA
CTD
PMID:17183730
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
G
Alox15
arachidonate 15-lipoxygenase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ALOX15 mRNA
CTD
PMID:17183730
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
G
Anapc11
anaphase promoting complex subunit 11
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANAPC11 mRNA
CTD
PMID:17183730
NCBI chr10:105,875,209...105,886,307
G
Andpro
androgen regulated protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CST4 mRNA
CTD
PMID:17183730
NCBI chr 3:136,718,601...136,725,131
Ensembl chr 3:136,718,602...136,724,966
G
Ankfn1
ankyrin-repeat and fibronectin type III domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKFN1 mRNA
CTD
PMID:17183730
NCBI chr10:74,214,143...74,602,825
Ensembl chr10:74,218,915...74,663,295
G
Ankhd1
ankyrin repeat and KH domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKHD1 mRNA
CTD
PMID:17183730
NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024
G
Ankib1
ankyrin repeat and IBR domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKIB1 mRNA
CTD
PMID:17183730
NCBI chr 4:30,333,678...30,457,781
Ensembl chr 4:30,333,677...30,457,781
G
Ankrd44
ankyrin repeat domain 44
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKRD44 mRNA
CTD
PMID:17183730
NCBI chr 9:56,126,746...56,427,661
Ensembl chr 9:56,126,747...56,427,508
G
Anxa2
annexin A2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANXA2 mRNA
CTD
PMID:17183730
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
G
Aoah
acyloxyacyl hydrolase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of AOAH mRNA
CTD
PMID:17183730
NCBI chr17:43,808,110...44,049,458
Ensembl chr17:43,809,638...44,049,148
G
Aoc1
amine oxidase, copper containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of AOC1 mRNA
CTD
PMID:17183730
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
G
Apc
APC regulator of WNT signaling pathway
decreases methylation
ISO
Hydralazine results in decreased methylation of APC promoter
CTD
PMID:15862127
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
G
Apcdd1l
APC down-regulated 1 like
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of APCDD1L mRNA
CTD
PMID:17183730
NCBI chr 3:162,587,484...162,658,362
Ensembl chr 3:162,582,252...162,658,073
G
Aqp10
aquaporin 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of AQP10 mRNA
CTD
PMID:17183730
NCBI chr 2:175,402,609...175,407,677
Ensembl chr 2:175,403,263...175,406,815
G
Arcn1
archain 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARCN1 mRNA
CTD
PMID:17183730
NCBI chr 8:45,057,617...45,082,224
Ensembl chr 8:45,057,619...45,082,247
G
Arf1
ADP-ribosylation factor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARF1 mRNA
CTD
PMID:17183730
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
G
Arhgap23
Rho GTPase activating protein 23
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP23 mRNA
CTD
PMID:17183730
NCBI chr10:82,437,578...82,496,846
Ensembl chr10:82,394,648...82,496,504
G
Arhgap40
Rho GTPase activating protein 40
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP40 mRNA
CTD
PMID:17183730
NCBI chr 3:147,165,781...147,206,552
Ensembl chr 3:147,165,729...147,207,203
G
Arhgap5
Rho GTPase activating protein 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP5 mRNA
CTD
PMID:17183730
NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660
G
Arhgef12
Rho guanine nucleotide exchange factor 12
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGEF12 mRNA
CTD
PMID:17183730
NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366
G
Arih2
ariadne RBR E3 ubiquitin protein ligase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARIH2 mRNA
CTD
PMID:17183730
NCBI chr 8:109,296,738...109,355,909
Ensembl chr 8:109,296,738...109,355,852
G
Arl2
ADP-ribosylation factor like GTPase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARL2 mRNA
CTD
PMID:17183730
NCBI chr 1:203,434,129...203,446,156
Ensembl chr 1:203,434,129...203,446,119
G
Arl6ip5
ADP-ribosylation factor like GTPase 6 interacting protein 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARL6IP5 mRNA
CTD
PMID:17183730
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
G
Art4
ADP-ribosyltransferase 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ART4 mRNA
CTD
PMID:17183730
NCBI chr 4:169,740,331...169,751,571
Ensembl chr 4:169,740,331...169,750,665
G
Asap3
ArfGAP with SH3 domain, ankyrin repeat and PH domain 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DDEFL1 mRNA
CTD
PMID:17183730
NCBI chr 5:148,433,382...148,476,027
Ensembl chr 5:148,433,494...148,474,073
G
Asb7
ankyrin repeat and SOCS box-containing 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ASB7 mRNA
CTD
PMID:17183730
NCBI chr 1:120,222,835...120,267,411
Ensembl chr 1:120,222,745...120,267,282
G
Asic4
acid sensing ion channel subunit family member 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ASIC4 mRNA
CTD
PMID:17183730
NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900
G
Asph
aspartate-beta-hydroxylase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ASPH mRNA
CTD
PMID:17183730
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
G
Atf3
activating transcription factor 3
multiple interactions
ISO
Hydralazine inhibits the reaction [Ethanol results in increased expression of ATF3 mRNA]
CTD
PMID:28119953
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
G
Atf4
activating transcription factor 4
multiple interactions
ISO
Hydralazine inhibits the reaction [Ethanol results in increased expression of ATF4 mRNA]
CTD
PMID:28119953
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
G
Atg10
autophagy related 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATG10 mRNA
CTD
PMID:17183730
NCBI chr 2:22,109,304...22,398,313
Ensembl chr 2:22,108,426...22,398,233
G
Atp13a4
ATPase 13A4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP13A4 mRNA
CTD
PMID:17183730
NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933
G
Atp5f1e
ATP synthase F1 subunit epsilon
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5F1E mRNA
CTD
PMID:17183730
NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450
G
Atp5mc3
ATP synthase membrane subunit c locus 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5MC3 mRNA
CTD
PMID:17183730
NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
G
Atp5me
ATP synthase membrane subunit e
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5ME mRNA
CTD
PMID:17183730
NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013
G
Atp5pf
ATP synthase peripheral stalk subunit F6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5PF mRNA
CTD
PMID:17183730
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
G
Atp6ap1
ATPase H+ transporting accessory protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6AP1 mRNA
CTD
PMID:17183730
NCBI chr X:152,079,954...152,087,034
Ensembl chr X:152,079,865...152,087,034
G
Atp6v1b1
ATPase H+ transporting V1 subunit B1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6V1B1 mRNA
CTD
PMID:17183730
NCBI chr 4:116,223,799...116,242,475
Ensembl chr 4:116,223,799...116,242,475
G
Atp6v1c1
ATPase H+ transporting V1 subunit C1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6V1C1 mRNA
CTD
PMID:17183730
NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278
G
Atxn2
ataxin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATXN2 mRNA
CTD
PMID:17183730
NCBI chr12:34,754,132...34,851,175
Ensembl chr12:34,754,137...34,851,479
G
Atxn7l1
ataxin 7-like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATXN7L1 mRNA
CTD
PMID:17183730
NCBI chr 6:49,759,876...49,982,323
Ensembl chr 6:49,759,883...49,982,320
G
B9d1
B9 domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of B9D1 mRNA
CTD
PMID:17183730
NCBI chr10:46,186,222...46,196,309
Ensembl chr10:46,186,691...46,196,008
G
Bad
BCL2-associated agonist of cell death
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of BAD mRNA
CTD
PMID:17183730
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
G
Bag1
BAG cochaperone 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of BAG1 mRNA
CTD
PMID:17183730
NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
G
Bckdk
branched chain ketoacid dehydrogenase kinase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of BCKDK mRNA
CTD
PMID:17183730
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
G
Bola1
bolA family member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of BOLA1 mRNA
CTD
PMID:17183730
NCBI chr 2:183,758,515...183,771,445
Ensembl chr 2:183,758,441...183,781,576
G
Bpgm
bisphosphoglycerate mutase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of BPGM mRNA
CTD
PMID:17183730
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
G
Bpifb2
BPI fold containing family B, member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of BPIFB2 mRNA
CTD
PMID:17183730
NCBI chr 3:142,356,990...142,377,053
Ensembl chr 3:142,358,051...142,377,044
G
Bptf
bromodomain PHD finger transcription factor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of BPTF mRNA
CTD
PMID:17183730
NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769
G
Brd8
bromodomain containing 8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of BRD8 mRNA
CTD
PMID:17183730
NCBI chr18:26,204,892...26,229,999
Ensembl chr18:26,181,732...26,229,884
G
C1qtnf5
C1q and TNF related 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of C1QTNF5 mRNA
CTD
PMID:17183730
NCBI chr 8:44,450,934...44,453,075
Ensembl chr 8:44,451,154...44,453,074
G
C4a
complement C4A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of C4A mRNA
CTD
PMID:17183730
NCBI chr20:4,005,731...4,020,083
Ensembl chr20:4,005,731...4,020,080
G
C5h9orf152
similar to human chromosome 9 open reading frame 152
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of C9ORF152 mRNA
CTD
PMID:17183730
NCBI chr 5:72,660,573...72,667,941
Ensembl chr 5:72,660,573...72,668,379
G
C8h3orf62
similar to human chromosome 3 open reading frame 62
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of C3ORF62 mRNA
CTD
PMID:17183730
NCBI chr 8:109,080,032...109,084,588
Ensembl chr 8:109,036,030...109,097,895
G
C9h6orf132
similar to human chromosome 6 open reading frame 132
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of C6ORF132 mRNA
CTD
PMID:17183730
NCBI chr 9:13,524,822...13,561,756
Ensembl chr 9:13,525,395...13,561,585
G
Cacng6
calcium voltage-gated channel auxiliary subunit gamma 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CACNG6 mRNA
CTD
PMID:17183730
NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341
G
Camlg
calcium modulating ligand
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CAMLG mRNA
CTD
PMID:17183730
NCBI chr17:8,992,697...9,003,576
Ensembl chr17:8,992,696...9,003,552
G
Canx
calnexin
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CANX mRNA
CTD
PMID:17183730
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
G
Car7
carbonic anhydrase 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CA7 mRNA
CTD
PMID:17183730
NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467
G
Car8
carbonic anhydrase 8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of CA8 mRNA
CTD
PMID:17183730
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
G
Casd1
CAS1 domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CASD1 mRNA
CTD
PMID:17183730
NCBI chr 4:32,659,196...32,739,228
Ensembl chr 4:32,658,748...32,739,202
G
Casp12
caspase 12
multiple interactions
ISO
Hydralazine inhibits the reaction [Ethanol results in increased cleavage of CASP12 protein]
CTD
PMID:28119953
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
G
Cbx7
chromobox 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CBX7 mRNA
CTD
PMID:17183730
NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973
G
Ccdc138
coiled-coil domain containing 138
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC138 mRNA
CTD
PMID:17183730
NCBI chr20:26,493,624...26,572,367
Ensembl chr20:26,495,235...26,572,376
G
Ccdc146
coiled-coil domain containing 146
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of CCDC146 mRNA
CTD
PMID:17183730
NCBI chr 4:13,662,766...13,811,619
Ensembl chr 4:13,662,766...13,811,608
G
Ccdc47
coiled-coil domain containing 47
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC47 mRNA
CTD
PMID:17183730
NCBI chr10:91,130,303...91,148,829
Ensembl chr10:91,130,303...91,148,881
G
Ccdc82
coiled-coil domain containing 82
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC82 mRNA
CTD
PMID:17183730
NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963
G
Ccl22
C-C motif chemokine ligand 22
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL22 mRNA
CTD
PMID:17183730
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
G
Ccl28
C-C motif chemokine ligand 28
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL28 mRNA
CTD
PMID:17183730
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
G
Ccl4
C-C motif chemokine ligand 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL4 mRNA
CTD
PMID:17183730
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
G
Ccm2
CCM2 scaffold protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCM2 mRNA
CTD
PMID:17183730
NCBI chr14:81,418,418...81,464,114
Ensembl chr14:81,418,236...81,464,116
G
Cct2
chaperonin containing TCP1 subunit 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCT2 mRNA
CTD
PMID:17183730
NCBI chr 7:52,692,725...52,705,478
Ensembl chr 7:52,692,725...52,706,944
G
Cct7
chaperonin containing TCP1 subunit 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCT7 mRNA
CTD
PMID:17183730
NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
G
Cd63
Cd63 molecule
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CD63 mRNA
CTD
PMID:17183730
NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178
G
Cdadc1
cytidine and dCMP deaminase domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDADC1 mRNA
CTD
PMID:17183730
NCBI chr15:33,726,590...33,755,611
Ensembl chr15:33,723,435...33,755,576
G
Cdc37
cell division cycle 37, HSP90 cochaperone
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDC37 mRNA
CTD
PMID:17183730
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
G
Cdc42
cell division cycle 42
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDC42 mRNA
CTD
PMID:17183730
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
G
Cdk12
cyclin-dependent kinase 12
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDK12 mRNA
CTD
PMID:17183730
NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888 Ensembl chr10:83,201,211...83,280,888
G
Cdk4
cyclin-dependent kinase 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDK4 mRNA
CTD
PMID:17183730
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
G
Cdkn1b
cyclin-dependent kinase inhibitor 1B
multiple interactions
EXP
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of CDKN1B protein
CTD
PMID:11318962
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
G
Cdkn2a
cyclin-dependent kinase inhibitor 2A
multiple interactions decreases methylation
EXP ISO
[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]; [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA] Hydralazine results in decreased methylation of CDKN2A promoter
CTD
PMID:15862127 PMID:18504326
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
G
Cdr2
cerebellar degeneration-related protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDR2 mRNA
CTD
PMID:17183730
NCBI chr 1:175,502,837...175,527,746
Ensembl chr 1:175,502,838...175,537,472
G
Cel
carboxyl ester lipase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CEL mRNA
CTD
PMID:17183730
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
G
Cenpn
centromere protein N
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CENPN mRNA
CTD
PMID:17183730
NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012
G
Cers5
ceramide synthase 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CERS5 mRNA
CTD
PMID:17183730
NCBI chr 7:130,859,993...130,897,979
Ensembl chr 7:130,859,990...130,897,947
G
Cfap300
cilia and flagella associated protein 300
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CFAP300 mRNA
CTD
PMID:17183730
NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807
G
Chchd10
coiled-coil-helix-coiled-coil-helix domain containing 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHCHD10 mRNA
CTD
PMID:17183730
NCBI chr20:12,725,839...12,727,638
Ensembl chr20:12,725,842...12,732,763
G
Chchd2
coiled-coil-helix-coiled-coil-helix domain containing 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHCHD2 mRNA
CTD
PMID:17183730
NCBI chr12:26,828,738...26,834,762
Ensembl chr12:26,828,736...26,834,755
G
Chd2
chromodomain helicase DNA binding protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHD2 mRNA
CTD
PMID:17183730
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
G
Chmp5
charged multivesicular body protein 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHMP5 mRNA
CTD
PMID:17183730
NCBI chr 5:56,081,385...56,098,529
Ensembl chr 5:56,081,343...56,098,529
G
Chn2
chimerin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHN2 mRNA
CTD
PMID:17183730
NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709
G
Chrna1
cholinergic receptor nicotinic alpha 1 subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHRNA1 mRNA
CTD
PMID:17183730
NCBI chr 3:58,454,763...58,469,832
Ensembl chr 3:58,454,744...58,469,840
G
Chst13
carbohydrate sulfotransferase 13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHST13 mRNA
CTD
PMID:17183730
NCBI chr 4:122,824,022...122,837,940
Ensembl chr 4:122,824,022...122,838,019
G
Cib1
calcium and integrin binding 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CIB1 mRNA
CTD
PMID:17183730
NCBI chr 1:134,178,331...134,183,895
Ensembl chr 1:134,178,331...134,213,423
G
Clasp2
cytoplasmic linker associated protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CLASP2 mRNA
CTD
PMID:17183730
NCBI chr 8:113,677,345...113,859,957
Ensembl chr 8:113,677,284...113,858,731
G
Clcn5
chloride voltage-gated channel 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CLCN5 mRNA
CTD
PMID:17183730
NCBI chr X:15,185,380...15,339,977
Ensembl chr X:15,185,451...15,334,264
G
Clybl
citramalyl-CoA lyase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CLYBL mRNA
CTD
PMID:17183730
NCBI chr15:99,283,644...99,505,697
Ensembl chr15:99,283,650...99,505,695
G
Cnnm3
cyclin and CBS domain divalent metal cation transport mediator 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CNNM3 mRNA
CTD
PMID:17183730
NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740
G
Coa3
cytochrome C oxidase assembly factor 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COA3 mRNA
CTD
PMID:17183730
NCBI chr10:86,220,192...86,221,173
Ensembl chr10:86,220,194...86,221,178
G
Cog5
component of oligomeric golgi complex 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COG5 mRNA
CTD
PMID:17183730
NCBI chr 6:48,242,470...48,545,185
Ensembl chr 6:48,242,482...48,529,009
G
Col1a1
collagen type I alpha 1 chain
decreases expression multiple interactions decreases expression
ISO EXP
Hydralazine results in decreased expression of COL1A1 mRNA [Hydralazine co-treated with Valproic Acid] results in increased expression of COL1A1 mRNA hydralazine decreases expression of Col1a1 mRNA in liver
CTD RGD
PMID:8941590 PMID:17183730 PMID:33315911
RGD:407420266
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
G
Col4a6
collagen type IV alpha 6 chain
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COL4A6 mRNA
CTD
PMID:17183730
NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500
G
Commd1
copper metabolism domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COMMD1 mRNA
CTD
PMID:17183730
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
G
Commd6
COMM domain containing 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COMMD6 mRNA
CTD
PMID:17183730
NCBI chr15:78,467,333...78,474,382
Ensembl chr15:78,467,804...78,474,382
G
Cope
COPI coat complex subunit epsilon
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COPE mRNA
CTD
PMID:17183730
NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907
G
Cops4
COP9 signalosome subunit 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COPS4 mRNA
CTD
PMID:17183730
NCBI chr14:9,078,579...9,108,788
Ensembl chr14:9,078,576...9,108,887
G
Coq4
coenzyme Q4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COQ4 mRNA
CTD
PMID:17183730
NCBI chr 3:13,060,054...13,070,502
Ensembl chr 3:13,060,455...13,068,799
G
Cox6b1
cytochrome c oxidase subunit 6B1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COX6B1 mRNA
CTD
PMID:17183730
NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001 Ensembl chr 2:85,875,109...85,884,001
G
Cox7c
cytochrome c oxidase subunit 7C
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of COX7C mRNA
CTD
PMID:17183730
NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
G
Cpt1a
carnitine palmitoyltransferase 1A
multiple interactions
EXP
Hydralazine inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA]
CTD
PMID:19109942
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
G
Creb5
cAMP responsive element binding protein 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CREB5 mRNA
CTD
PMID:17183730
NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325
G
Cryba4
crystallin, beta A4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CRYBA4 mRNA
CTD
PMID:17183730
NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221
G
Ctcf
CCCTC-binding factor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of CTCF mRNA
CTD
PMID:17183730
NCBI chr19:33,521,726...33,571,124
Ensembl chr19:33,529,319...33,571,123
G
Ctnnd1
catenin delta 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CTNND1 mRNA
CTD
PMID:17183730
NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516
G
Ctsk
cathepsin K
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CTSK mRNA
CTD
PMID:17183730
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
G
Cuedc2
CUE domain containing 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CUEDC2 mRNA
CTD
PMID:17183730
NCBI chr 1:245,192,057...245,200,594
Ensembl chr 1:245,192,063...245,200,339
G
Cul1
cullin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CUL1 mRNA
CTD
PMID:17183730
NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980
G
Cyb5r1
cytochrome b5 reductase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYB5R1 mRNA
CTD
PMID:17183730
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
G
Cyb5r3
cytochrome b5 reductase 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYB5R3 mRNA
CTD
PMID:17183730
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
G
Cyfip2
cytoplasmic FMR1 interacting protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYFIP2 mRNA
CTD
PMID:17183730
NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
multiple interactions
EXP ISO
Hydralazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
CTD
PMID:18493746
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
multiple interactions
ISO EXP
Hydralazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]
CTD
PMID:18493746
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp2a3
cytochrome P450, family 2, subfamily a, polypeptide 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP2A7 mRNA
CTD
PMID:17183730
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
G
Cyp4x1
cytochrome P450, family 4, subfamily x, polypeptide 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP4X1 mRNA
CTD
PMID:17183730
NCBI chr 5:128,651,681...128,683,338
Ensembl chr 5:128,651,776...128,682,779
G
Dact2
dishevelled-binding antagonist of beta-catenin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DACT2 mRNA
CTD
PMID:17183730
NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096
G
Dancr
differentiation antagonizing non-protein coding RNA
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DANCR mRNA
CTD
PMID:17183730
NCBI chr14:34,126,956...34,127,936
G
Dapk1
death associated protein kinase 1
decreases methylation increases expression
ISO
Hydralazine results in decreased methylation of DAPK1 promoter Hydralazine results in increased expression of DAPK1 mRNA
CTD
PMID:15862127
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
G
Dbf4b
DBF4B-CDC7 kinase regulatory subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DBF4B mRNA
CTD
PMID:17183730
NCBI chr10:87,713,805...87,719,197
G
Dbi
diazepam binding inhibitor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DBI mRNA
CTD
PMID:17183730
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
G
Dcaf8
DDB1 and CUL4 associated factor 8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DCAF8 mRNA
CTD
PMID:17183730
NCBI chr13:84,609,838...84,667,025
Ensembl chr13:84,610,248...84,669,726
G
Dclre1c
DNA cross-link repair 1C
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DCLRE1C mRNA
CTD
PMID:17183730
NCBI chr17:74,775,828...74,810,089
Ensembl chr17:74,776,935...74,809,186
G
Dcp1a
decapping mRNA 1A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DCP1A mRNA
CTD
PMID:17183730
NCBI chr16:5,656,960...5,702,151
Ensembl chr16:5,656,773...5,702,140
G
Ddit3
DNA-damage inducible transcript 3
multiple interactions
ISO
Hydralazine inhibits the reaction [Ethanol results in increased expression of DDIT3 mRNA]; Hydralazine inhibits the reaction [Ethanol results in increased expression of DDIT3 protein]
CTD
PMID:28119953
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
G
Ddt
D-dopachrome tautomerase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DDT mRNA
CTD
PMID:17183730
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
G
Ddx27
DEAD-box helicase 27
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DDX27 mRNA
CTD
PMID:17183730
NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372
G
Ddx46
DEAD-box helicase 46
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DDX46 mRNA
CTD
PMID:17183730
NCBI chr17:8,942,070...8,988,440
Ensembl chr17:8,944,454...8,988,439
G
Dlat
dihydrolipoamide S-acetyltransferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of DLAT mRNA
CTD
PMID:17183730
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
G
Dnaaf5
dynein, axonemal, assembly factor 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of DNAAF5 mRNA
CTD
PMID:17183730
NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739
G
Dnah14
dynein axonemal heavy chain 14
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAH14 mRNA
CTD
PMID:17183730
NCBI chr13:93,322,653...93,540,706
Ensembl chr13:93,322,711...93,538,646
G
Dnaja3
DnaJ heat shock protein family (Hsp40) member A3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJA3 mRNA
CTD
PMID:17183730
NCBI chr10:10,854,732...10,880,171
Ensembl chr10:10,854,732...10,880,161
G
Dnajc3
DnaJ heat shock protein family (Hsp40) member C3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJC3 mRNA
CTD
PMID:17183730
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
G
Dnajc8
DnaJ heat shock protein family (Hsp40) member C8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJC8 mRNA
CTD
PMID:17183730
NCBI chr 5:144,745,055...144,763,106
Ensembl chr 5:144,745,036...144,763,108
G
Dnhd1
dynein heavy chain domain 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNHD1 mRNA
CTD
PMID:17183730
NCBI chr 1:159,990,785...160,077,990
Ensembl chr 1:159,990,438...160,074,858
G
Dpy19l3
dpy-19 like C-mannosyltransferase 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DPY19L3 mRNA
CTD
PMID:17183730
NCBI chr 1:88,350,303...88,417,339
Ensembl chr 1:88,350,303...88,417,339
G
Drd4
dopamine receptor D4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DRD4 mRNA
CTD
PMID:17183730
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
G
Dscc1
DNA replication and sister chromatid cohesion 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DSCC1 mRNA
CTD
PMID:17183730
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
G
Dync1li1
dynein cytoplasmic 1 light intermediate chain 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DYNC1LI1 mRNA
CTD
PMID:17183730
NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934
G
Dynll1
dynein light chain LC8-type 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of DYNLL1 mRNA
CTD
PMID:17183730
NCBI chr12:41,312,365...41,316,157
Ensembl chr12:41,312,367...41,314,741
G
Edn1
endothelin 1
multiple interactions
EXP
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA]
CTD
PMID:16326922
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
G
Eef1d
eukaryotic translation elongation factor 1 delta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EEF1D mRNA
CTD
PMID:17183730
NCBI chr 7:107,581,930...107,596,735
Ensembl chr 7:107,581,930...107,608,799
G
Efhb
EF hand domain family, member B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EFHB mRNA
CTD
PMID:17183730
NCBI chr 9:6,372,191...6,441,678
Ensembl chr 9:6,372,194...6,441,919
G
Efhd2
EF-hand domain family, member D2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EFHD2 mRNA
CTD
PMID:17183730
NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980
G
Ehmt2
euchromatic histone lysine methyltransferase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EHMT2 mRNA
CTD
PMID:17183730
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
G
Eif3l
eukaryotic translation initiation factor 3, subunit L
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF3L mRNA
CTD
PMID:17183730
NCBI chr 7:110,652,565...110,663,614
Ensembl chr 7:110,627,107...110,663,614
G
Eif4b
eukaryotic translation initiation factor 4B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF4B mRNA
CTD
PMID:17183730
NCBI chr 7:133,206,637...133,228,436
G
Eif4g3
eukaryotic translation initiation factor 4 gamma, 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF4G3 mRNA
CTD
PMID:17183730
NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363
G
Elk3
ETS transcription factor ELK3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ELK3 mRNA
CTD
PMID:17183730
NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084
G
Ell
elongation factor for RNA polymerase II
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ELL mRNA
CTD
PMID:17183730
NCBI chr16:18,843,775...18,891,484
Ensembl chr16:18,843,780...18,891,118
G
Ell3
elongation factor for RNA polymerase II 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ELL3 mRNA
CTD
PMID:17183730
NCBI chr 3:108,413,035...108,417,181
Ensembl chr 3:108,410,448...108,417,132
G
Eln
elastin
multiple interactions
EXP
[Isoproterenol co-treated with Hydralazine] results in increased expression of ELN protein
CTD
PMID:3446201
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
G
Elob
elongin B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ELOB mRNA
CTD
PMID:17183730
NCBI chr10:12,848,830...12,853,897
Ensembl chr10:12,848,827...12,853,635
G
Elovl6
ELOVL fatty acid elongase 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ELOVL6 mRNA
CTD
PMID:17183730
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
G
Emp3
epithelial membrane protein 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EMP3 mRNA
CTD
PMID:17183730
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
G
Epas1
endothelial PAS domain protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPAS1 mRNA
CTD
PMID:17183730
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
G
Epc1
enhancer of polycomb homolog 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPC1 mRNA
CTD
PMID:17183730
NCBI chr17:54,503,358...54,594,444
Ensembl chr17:54,503,358...54,594,425
G
Epha8
Eph receptor A8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPHA8 mRNA
CTD
PMID:17183730
NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399
G
Epn2
epsin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPN2 mRNA
CTD
PMID:17183730
NCBI chr10:46,197,785...46,259,673
Ensembl chr10:46,197,785...46,259,642
G
Eprs1
glutamyl-prolyl-tRNA synthetase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPRS1 mRNA
CTD
PMID:17183730
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
G
Erlec1
endoplasmic reticulum lectin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ERLEC1 mRNA
CTD
PMID:17183730
NCBI chr14:104,655,745...104,693,508
Ensembl chr14:104,655,673...104,693,480
G
Ero1b
endoplasmic reticulum oxidoreductase 1 beta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ERO1B mRNA
CTD
PMID:17183730
NCBI chr17:85,861,086...86,003,244
Ensembl chr17:85,929,618...86,003,398
G
Esr1
estrogen receptor 1
decreases methylation increases expression multiple interactions
ISO
Hydralazine results in decreased methylation of ESR1 promoter Hydralazine results in increased expression of ESR1 mRNA Hydralazine inhibits the reaction [3-methylquinoline results in increased activity of ESR1 protein]; Hydralazine inhibits the reaction [8-methylquinoline results in increased activity of ESR1 protein]
CTD
PMID:15862127 PMID:30896932
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Etl4
enhancer trap locus 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of KIAA1217 mRNA
CTD
PMID:17183730
NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715
G
Exoc3l2
exocyst complex component 3-like 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EXOC3L2 mRNA
CTD
PMID:17183730
NCBI chr 1:79,113,784...79,145,359
Ensembl chr 1:79,112,506...79,145,465
G
Exoc7
exocyst complex component 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EXOC7 mRNA
CTD
PMID:17183730
NCBI chr10:101,521,630...101,540,425
Ensembl chr10:101,520,927...101,540,561
G
F11r
F11 receptor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of F11R mRNA
CTD
PMID:17183730
NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402
G
F12
coagulation factor XII
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of F12 mRNA
CTD
PMID:17183730
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
G
Fam120a
family with sequence similarity 120 member A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM120A mRNA
CTD
PMID:17183730
NCBI chr17:15,684,233...15,774,964
Ensembl chr17:15,684,233...15,774,964
G
Fam13b
family with sequence similarity 13, member B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM13B mRNA
CTD
PMID:17183730
NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587
G
Fam162a
family with sequence similarity 162, member A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM162A mRNA
CTD
PMID:17183730
NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239
G
Fam163a
family with sequence similarity 163, member A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of FAM163A mRNA
CTD
PMID:17183730
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049
G
Fam210b
family with sequence similarity 210, member B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM210B mRNA
CTD
PMID:17183730
NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397
G
Fam241b
family with sequence similarity 241 member B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM241B mRNA
CTD
PMID:17183730
NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
G
Fam3a
FAM3 metabolism regulating signaling molecule A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM3A mRNA
CTD
PMID:17183730
NCBI chr X:152,166,716...152,175,327
Ensembl chr X:152,165,535...152,175,362
G
Fam50a
family with sequence similarity 50, member A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM50A mRNA
CTD
PMID:17183730
NCBI chr X:152,095,245...152,102,362
Ensembl chr X:152,095,245...152,102,362
G
Faslg
Fas ligand
multiple interactions
ISO EXP
Hydralazine inhibits the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Acrolein results in increased expression of FASLG mRNA]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Zidovudine results in increased expression of FASLG mRNA] Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Acrolein results in increased expression of FASLG mRNA]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Zidovudine results in increased expression of FASLG mRNA]
CTD
PMID:27238871
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
G
Fbrsl1
fibrosin-like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FBRSL1 mRNA
CTD
PMID:17183730
NCBI chr12:46,231,466...46,320,607
Ensembl chr12:46,231,495...46,320,357
G
Fbxw4
F-box and WD repeat domain containing 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FBXW4 mRNA
CTD
PMID:17183730
NCBI chr 1:244,426,892...244,514,188
Ensembl chr 1:244,426,896...244,514,163
G
Fdps
farnesyl diphosphate synthase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FDPS mRNA
CTD
PMID:17183730
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
G
Ffar3
free fatty acid receptor 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FFAR3 mRNA
CTD
PMID:17183730
NCBI chr 1:86,105,388...86,106,728
Ensembl chr 1:86,104,920...86,106,849
G
Fhit
fragile histidine triad diadenosine triphosphatase
decreases methylation increases expression
ISO
Hydralazine results in decreased methylation of FHIT promoter Hydralazine results in increased expression of FHIT mRNA
CTD
PMID:15862127
NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340
G
Fis1
fission, mitochondrial 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FIS1 mRNA
CTD
PMID:17183730
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
G
Flot1
flotillin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FLOT1 mRNA
CTD
PMID:17183730
NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978
G
Flt1
Fms related receptor tyrosine kinase 1
multiple interactions
EXP
[Hydralazine co-treated with Hydrochlorothiazide] inhibits the reaction [Cyclosporine results in increased expression of FLT1 mRNA]
CTD
PMID:12110003
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
G
Fos
Fos proto-oncogene, AP-1 transcription factor subunit
affects expression
EXP
Hydralazine affects the expression of FOS protein
CTD
PMID:8750937
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
G
Foxp1
forkhead box P1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FOXP1 mRNA
CTD
PMID:17183730
NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258
G
Foxp2
forkhead box P2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of FOXP2 mRNA
CTD
PMID:17183730
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
G
Foxp3
forkhead box P3
increases expression
ISO
Hydralazine results in increased expression of FOXP3 protein
CTD
PMID:19109157
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
G
Fst
follistatin
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FST mRNA
CTD
PMID:17183730
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
G
Fstl5
follistatin-like 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FSTL5 mRNA
CTD
PMID:17183730
NCBI chr 2:160,857,989...161,526,589
Ensembl chr 2:160,856,291...161,526,589
G
Fth1
ferritin heavy chain 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FTH1 mRNA
CTD
PMID:17183730
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
G
Fthl17a
ferritin, heavy polypeptide-like 17, member A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FTHL17 mRNA
CTD
PMID:17183730
NCBI chr X:49,595,422...49,596,399
Ensembl chr X:49,595,718...49,596,266
G
Fxyd5
FXYD domain-containing ion transport regulator 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of FXYD5 mRNA
CTD
PMID:17183730
NCBI chr 1:86,267,937...86,277,329
Ensembl chr 1:86,267,406...86,277,519
G
Gabarap
GABA type A receptor-associated protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GABARAP mRNA
CTD
PMID:17183730
NCBI chr10:54,714,777...54,718,099
Ensembl chr10:54,714,198...54,717,765
G
Galnt7
polypeptide N-acetylgalactosaminyltransferase 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GALNT7 mRNA
CTD
PMID:17183730
NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690
G
Galp
galanin-like peptide
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GALP mRNA
CTD
PMID:17183730
NCBI chr 1:67,684,023...67,703,121
Ensembl chr 1:67,684,025...67,702,269
G
Gamt
guanidinoacetate N-methyltransferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GAMT mRNA
CTD
PMID:17183730
NCBI chr 7:9,448,590...9,451,413
Ensembl chr 7:9,448,628...9,451,778
G
Ganab
glucosidase II alpha subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GANAB mRNA
CTD
PMID:17183730
NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695
G
Gatd3a
glutamine amidotransferase class 1 domain containing 3A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GATD3 mRNA
CTD
PMID:17183730
NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885
G
Gfra2
GDNF family receptor alpha 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GFRA2 mRNA
CTD
PMID:17183730
NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714
G
Gfra3
GDNF family receptor alpha 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GFRA3 mRNA
CTD
PMID:17183730
NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105
G
Gjd4
gap junction protein, delta 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GJD4 mRNA
CTD
PMID:17183730
NCBI chr17:57,348,844...57,352,601
Ensembl chr17:57,349,877...57,352,446
G
Gla
galactosidase, alpha
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GLA mRNA
CTD
PMID:17183730
NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664
G
Gnpat
glyceronephosphate O-acyltransferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GNPAT mRNA
CTD
PMID:17183730
NCBI chr19:52,822,326...52,848,872
Ensembl chr19:52,822,319...52,852,361
G
Golgb1
golgin B1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GOLGB1 mRNA
CTD
PMID:17183730
NCBI chr11:63,843,179...63,900,665
Ensembl chr11:63,843,986...63,900,770
G
Golm2
golgi membrane protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GOLM2 mRNA
CTD
PMID:17183730
NCBI chr 3:108,827,017...108,896,207
Ensembl chr 3:108,827,047...108,896,207
G
Gp2
glycoprotein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GP2 mRNA
CTD
PMID:17183730
NCBI chr 1:173,797,057...173,812,619
Ensembl chr 1:173,797,057...173,812,619
G
Gpaa1
glycosylphosphatidylinositol anchor attachment 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of GPAA1 mRNA
CTD
PMID:17183730
NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484
G
Gpbp1l1
GC-rich promoter binding protein 1-like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GPBP1L1 mRNA
CTD
PMID:17183730
NCBI chr 5:130,009,768...130,050,636
Ensembl chr 5:130,023,137...130,050,459
G
Gpr83
G protein-coupled receptor 83
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GPR83 mRNA
CTD
PMID:17183730
NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:11,693,540...11,704,028
G
Gps2
G protein pathway suppressor 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GPS2 mRNA
CTD
PMID:17183730
NCBI chr10:54,637,360...54,640,542
Ensembl chr10:54,637,455...54,640,650
G
Gpt
glutamic--pyruvic transaminase
multiple interactions
ISO
Hydralazine inhibits the reaction [Ethanol results in increased expression of GPT protein]
CTD
PMID:28119953
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
G
Grap
GRB2-related adaptor protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GRAP mRNA
CTD
PMID:17183730
NCBI chr10:46,298,965...46,352,057
Ensembl chr10:46,332,909...46,352,056
G
Grk3
G protein-coupled receptor kinase 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of GRK3 mRNA
CTD
PMID:17183730
NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262
G
Grk4
G protein-coupled receptor kinase 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GRK4 mRNA
CTD
PMID:17183730
NCBI chr14:75,998,554...76,080,808
Ensembl chr14:76,006,218...76,080,693
G
Grwd1
glutamate-rich WD repeat containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GRWD1 mRNA
CTD
PMID:17183730
NCBI chr 1:96,301,260...96,306,962
Ensembl chr 1:96,301,261...96,307,201
G
Gsn
gelsolin
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GSN mRNA
CTD
PMID:17183730
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
G
Gstp1
glutathione S-transferase pi 1
decreases methylation increases expression
ISO
Hydralazine results in decreased methylation of GSTP1 promoter Hydralazine results in increased expression of GSTP1 mRNA
CTD
PMID:15862127
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
G
Gstt2
glutathione S-transferase theta 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GSTT2 mRNA
CTD
PMID:17183730
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
G
Guk1
guanylate kinase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of GUK1 mRNA
CTD
PMID:17183730
NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107
G
H3f3a
H3.3 histone A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of H3-3A mRNA
CTD
PMID:17183730
NCBI chr13:92,533,289...92,544,902
Ensembl chr13:92,533,298...92,544,908
G
Haao
3-hydroxyanthranilate 3,4-dioxygenase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HAAO mRNA
CTD
PMID:17183730
NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877
G
Hba-a2
hemoglobin alpha, adult chain 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBA1 mRNA
CTD
PMID:17183730
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
G
Hbb
hemoglobin subunit beta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBB mRNA
CTD
PMID:17183730
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
G
Hbz
hemoglobin subunit zeta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBZ mRNA
CTD
PMID:17183730
NCBI chr10:15,343,821...15,345,301
Ensembl chr10:15,343,831...15,345,312
G
Hcfc1r1
host cell factor C1 regulator 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HCFC1R1 mRNA
CTD
PMID:17183730
NCBI chr10:12,705,139...12,706,852
Ensembl chr10:12,705,077...12,706,850
G
Hdgfl1
HDGF like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HDGFL1 mRNA
CTD
PMID:17183730
NCBI chr17:38,207,906...38,209,902
G
Heatr5b
HEAT repeat containing 5B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of HEATR5B mRNA
CTD
PMID:17183730
NCBI chr 6:16,243,424...16,323,444
Ensembl chr 6:16,243,461...16,323,435
G
Hebp1
heme binding protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HEBP1 mRNA
CTD
PMID:17183730
NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854
G
Henmt1
HEN methyltransferase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HENMT1 mRNA
CTD
PMID:17183730
NCBI chr 2:196,585,732...196,603,700
Ensembl chr 2:196,586,797...196,599,738
G
Hfe
homeostatic iron regulator
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HFE mRNA
CTD
PMID:17183730
NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502
G
Higd2a
HIG1 hypoxia inducible domain family, member 2A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HIGD2A mRNA
CTD
PMID:17183730
NCBI chr17:10,021,853...10,022,777
Ensembl chr17:10,021,859...10,022,796
G
Hinfp
histone H4 transcription factor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HINFP mRNA
CTD
PMID:17183730
NCBI chr 8:44,634,333...44,644,288
Ensembl chr 8:44,634,333...44,641,000
G
Hint1
histidine triad nucleotide binding protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HINT1 mRNA
CTD
PMID:17183730
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
G
Hint2
histidine triad nucleotide binding protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HINT2 mRNA
CTD
PMID:17183730
NCBI chr 5:57,904,613...57,906,868
Ensembl chr 5:57,904,614...57,907,097
G
Hk1
hexokinase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HK1 mRNA
CTD
PMID:17183730
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
G
Hmgcl
3-hydroxy-3-methylglutaryl-CoA lyase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HMGCL mRNA
CTD
PMID:17183730
NCBI chr 5:148,178,203...148,192,072
Ensembl chr 5:148,178,252...148,192,068
G
Hmgxb4
HMG-box containing 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HMGXB4 mRNA
CTD
PMID:17183730
NCBI chr19:13,364,741...13,403,563
Ensembl chr19:13,364,807...13,403,563
G
Hmox1
heme oxygenase 1
multiple interactions
ISO
Hydralazine inhibits the reaction [[Acrolein binds to ALB protein] which results in increased expression of HMOX1 mRNA]
CTD
PMID:32530271
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
G
Hps3
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HPS3 mRNA
CTD
PMID:17183730
NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
G
Hpse
heparanase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HPSE mRNA
CTD
PMID:17183730
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
G
Hsbp1
heat shock factor binding protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HSBP1 mRNA
CTD
PMID:17183730
NCBI chr19:47,401,039...47,405,373
Ensembl chr19:47,400,966...47,435,821
G
Hspa5
heat shock protein family A (Hsp70) member 5
multiple interactions
ISO
Hydralazine inhibits the reaction [Ethanol results in increased expression of HSPA5 mRNA]
CTD
PMID:28119953
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
G
Hspa8
heat shock protein family A (Hsp70) member 8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HSPA8 mRNA
CTD
PMID:17183730
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
G
Hyi
hydroxypyruvate isomerase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HYI mRNA
CTD
PMID:17183730
NCBI chr 5:131,894,575...131,897,709
Ensembl chr 5:131,894,598...131,897,251
G
Icam1
intercellular adhesion molecule 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ICAM1 mRNA
CTD
PMID:17183730
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
G
Icmt
isoprenylcysteine carboxyl methyltransferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ICMT mRNA
CTD
PMID:17183730
NCBI chr 5:162,804,368...162,811,129
Ensembl chr 5:162,804,368...162,811,128
G
Idh3g
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IDH3G mRNA
CTD
PMID:17183730
NCBI chr X:151,515,244...151,524,175
Ensembl chr X:151,515,247...151,524,171
G
Ifitm2
interferon induced transmembrane protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IFITM2 mRNA
CTD
PMID:17183730
NCBI chr 1:196,051,539...196,052,719
Ensembl chr 1:196,051,537...196,052,741
G
Ifrd1
interferon-related developmental regulator 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IFRD1 mRNA
CTD
PMID:17183730
NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
G
Ift22
intraflagellar transport 22
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IFT22 mRNA
CTD
PMID:17183730
NCBI chr12:19,759,072...19,768,859
Ensembl chr12:19,761,790...19,768,809
G
Ift57
intraflagellar transport 57
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IFT57 mRNA
CTD
PMID:17183730
NCBI chr11:51,051,520...51,124,909
Ensembl chr11:51,059,611...51,124,812
G
Igbp1
immunoglobulin binding protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IGBP1 mRNA
CTD
PMID:17183730
NCBI chr X:65,582,832...65,605,078
Ensembl chr X:65,582,821...65,606,049
G
Igf2bp2
insulin-like growth factor 2 mRNA binding protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IGF2BP2 mRNA
CTD
PMID:17183730
NCBI chr11:78,874,402...78,974,392
Ensembl chr11:78,874,414...78,974,377
G
Il10
interleukin 10
increases secretion
ISO
Hydralazine results in increased secretion of IL10 protein
CTD
PMID:16612254
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
G
Il1rapl2
interleukin 1 receptor accessory protein-like 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IL1RAPL2 mRNA
CTD
PMID:17183730
NCBI chr X:100,961,509...102,271,753
Ensembl chr X:100,961,812...102,271,753
G
Il3
interleukin 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of IL3 mRNA
CTD
PMID:17183730
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
G
Il6
interleukin 6
decreases secretion increases expression
ISO
Hydralazine results in decreased secretion of IL6 protein Hydralazine results in increased expression of IL6 protein
CTD
PMID:16612254 PMID:19575532
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Inava
innate immunity activator
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of INAVA mRNA
CTD
PMID:17183730
NCBI chr13:47,666,446...47,687,383
Ensembl chr13:47,666,447...47,686,729
G
Ino80e
INO80 complex subunit E
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of INO80E mRNA
CTD
PMID:17183730
NCBI chr 1:181,461,406...181,472,059
Ensembl chr 1:181,461,408...181,472,469
G
Irf7
interferon regulatory factor 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IRF7 mRNA
CTD
PMID:17183730
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
G
Irx3
iroquois homeobox 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of IRX3 mRNA
CTD
PMID:17183730
NCBI chr19:15,211,882...15,215,317
Ensembl chr19:15,211,878...15,215,317
G
Isca2
iron-sulfur cluster assembly 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ISCA2 mRNA
CTD
PMID:17183730
NCBI chr 6:104,418,509...104,420,019
Ensembl chr 6:104,418,454...104,420,045
G
Itgam
integrin subunit alpha M
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ITGAM mRNA
CTD
PMID:17183730
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
G
Itsn1
intersectin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ITSN1 mRNA
CTD
PMID:17183730
NCBI chr11:30,978,590...31,160,645
Ensembl chr11:30,978,590...31,160,645
G
Itsn2
intersectin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ITSN2 mRNA
CTD
PMID:17183730
NCBI chr 6:27,616,645...27,727,373
Ensembl chr 6:27,600,406...27,727,124
G
Jarid2
jumonji and AT-rich interaction domain containing 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of JARID2 mRNA
CTD
PMID:17183730
NCBI chr17:19,777,487...19,957,696
Ensembl chr17:19,777,266...19,955,690
G
Jmjd1c
jumonji domain containing 1C
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of JMJD1C mRNA
CTD
PMID:17183730
NCBI chr20:21,332,147...21,494,220
Ensembl chr20:21,332,147...21,463,122
G
Kank1
KN motif and ankyrin repeat domains 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of KANK1 mRNA
CTD
PMID:17183730
NCBI chr 1:222,877,962...223,074,514
Ensembl chr 1:222,877,622...223,074,514
G
Kank4
KN motif and ankyrin repeat domains 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of KANK4 mRNA
CTD
PMID:17183730
NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555
G
Kcna7
potassium voltage-gated channel subfamily A member 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of KCNA7 mRNA
CTD
PMID:17183730
NCBI chr 1:95,886,073...95,891,565
Ensembl chr 1:95,886,073...95,891,565
G
Kdelr3
KDEL endoplasmic reticulum protein retention receptor 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of KDELR3 mRNA
CTD
PMID:17183730
NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600
G
Kiaa0586
KIAA0586 homolog
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of KIAA0586 mRNA
CTD
PMID:17183730
NCBI chr 6:89,622,711...89,725,951
Ensembl chr 6:89,623,699...89,725,962
G
Klf6
KLF transcription factor 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of KLF6 mRNA
CTD
PMID:17183730
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
G
Klhl9
kelch-like family member 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of KLHL9 mRNA
CTD
PMID:17183730
NCBI chr 5:103,333,747...103,337,931
G
Krt17
keratin 17
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of KRT17 mRNA
CTD
PMID:17183730
NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392
G
Lasp1
LIM and SH3 protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LASP1 mRNA
CTD
PMID:17183730
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
G
Lef1
lymphoid enhancer binding factor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LEF1 mRNA
CTD
PMID:17183730
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
G
Lgals1
galectin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LGALS1 mRNA
CTD
PMID:17183730
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
G
Lgals2
galectin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LGALS2 mRNA
CTD
PMID:17183730
NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802
G
Lgr4
leucine-rich repeat-containing G protein-coupled receptor 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LGR4 mRNA
CTD
PMID:17183730
NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899
G
Lhfpl5
LHFPL tetraspan subfamily member 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LHFPL5 mRNA
CTD
PMID:17183730
NCBI chr20:6,632,324...6,642,534
Ensembl chr20:6,632,362...6,642,532
G
Lin37
lin-37 DREAM MuvB core complex component
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LIN37 mRNA
CTD
PMID:17183730
NCBI chr 1:85,809,065...85,813,235
Ensembl chr 1:85,809,074...85,812,991
G
LOC103693823
epididymal secretory protein E3-beta-like
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of EDDM3A mRNA
CTD
PMID:17183730
NCBI chr15:24,385,585...24,386,643
Ensembl chr15:24,386,192...24,386,623
G
Lpcat4
lysophosphatidylcholine acyltransferase 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LPCAT4 mRNA
CTD
PMID:17183730
NCBI chr 3:99,044,729...99,052,963
Ensembl chr 3:99,044,729...99,052,875
G
Lpgat1
lysophosphatidylglycerol acyltransferase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LPGAT1 mRNA
CTD
PMID:17183730
NCBI chr13:103,294,622...103,365,372
Ensembl chr13:103,294,528...103,362,333
G
Lpin3
lipin 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LPIN3 mRNA
CTD
PMID:17183730
NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327
G
Lpp
LIM domain containing preferred translocation partner in lipoma
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LPP mRNA
CTD
PMID:17183730
NCBI chr11:75,787,326...76,426,646
Ensembl chr11:75,797,078...76,422,597
G
Lrfn1
leucine rich repeat and fibronectin type III domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRFN1 mRNA
CTD
PMID:17183730
NCBI chr 1:83,742,442...83,761,450
Ensembl chr 1:83,682,964...83,761,449
G
Lrp10
LDL receptor related protein 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRP10 mRNA
CTD
PMID:17183730
NCBI chr15:27,921,335...27,927,507
Ensembl chr15:27,920,259...27,927,505
G
Lrrc40
leucine rich repeat containing 40
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC40 mRNA
CTD
PMID:17183730
NCBI chr 2:247,101,518...247,131,061
Ensembl chr 2:247,101,500...247,131,059
G
Lrrc8e
leucine rich repeat containing 8 VRAC subunit E
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC8E mRNA
CTD
PMID:17183730
NCBI chr12:2,578,240...2,589,407
Ensembl chr12:2,578,315...2,589,412
G
Luc7l3
LUC7-like 3 pre-mRNA splicing factor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of CROP mRNA
CTD
PMID:17183730
NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538
G
Ly86
lymphocyte antigen 86
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of LY86 mRNA
CTD
PMID:17183730
NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260
G
Maoa
monoamine oxidase A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MAOA mRNA
CTD
PMID:17183730
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
G
Map2k3
mitogen activated protein kinase kinase 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MAP2K3 mRNA
CTD
PMID:17183730
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
G
Mapk1
mitogen activated protein kinase 1
multiple interactions
EXP
Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK1 protein]
CTD
PMID:16344371
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
multiple interactions
EXP
Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK3 protein]
CTD
PMID:16344371
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
G
Mark3
microtubule affinity regulating kinase 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MARK3 mRNA
CTD
PMID:17183730
NCBI chr 6:130,626,612...130,716,245
Ensembl chr 6:130,627,482...130,716,647
G
Mas1
MAS1 proto-oncogene, G protein-coupled receptor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MAS1 mRNA
CTD
PMID:17183730
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
G
Mbd6
methyl-CpG binding domain protein 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MBD6 mRNA
CTD
PMID:17183730
NCBI chr 7:63,107,562...63,115,841
Ensembl chr 7:63,107,562...63,113,274
G
Mboat7
membrane bound O-acyltransferase domain containing 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MBOAT7 mRNA
CTD
PMID:17183730
NCBI chr 1:65,525,206...65,539,538
Ensembl chr 1:65,525,213...65,539,538
G
Me2
malic enzyme 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ME2 mRNA
CTD
PMID:17183730
NCBI chr18:67,350,833...67,400,987
Ensembl chr18:67,355,795...67,400,987
G
Med8
mediator complex subunit 8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MED8 mRNA
CTD
PMID:17183730
NCBI chr 5:131,948,632...131,949,516
Ensembl chr 5:131,943,982...131,950,305
G
Mettl3
methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of METTL3 mRNA
CTD
PMID:17183730
NCBI chr15:25,002,505...25,014,097
Ensembl chr15:25,003,172...25,014,041
G
Mettl6
methyltransferase 6, tRNA N3-cytidine
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of METTL6 mRNA
CTD
PMID:17183730
NCBI chr16:6,683,820...6,699,013
Ensembl chr16:6,583,465...6,698,975
G
Mfsd5
major facilitator superfamily domain containing 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MFSD5 mRNA
CTD
PMID:17183730
NCBI chr 7:133,409,096...133,411,377
Ensembl chr 7:133,402,537...133,411,396
G
Mgat1
alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MGAT1 mRNA
CTD
PMID:17183730
NCBI chr10:33,563,642...33,582,718
Ensembl chr10:33,561,388...33,591,503
G
Mgmt
O-6-methylguanine-DNA methyltransferase
decreases methylation increases expression
ISO
Hydralazine results in decreased methylation of MGMT promoter Hydralazine results in increased expression of MGMT mRNA
CTD
PMID:15862127
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
G
Mgp
matrix Gla protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MGP mRNA
CTD
PMID:17183730
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
G
Mical3
microtubule associated monooxygenase, calponin and LIM domain containing 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MICAL3 mRNA
CTD
PMID:17183730
NCBI chr 4:154,152,776...154,353,274
Ensembl chr 4:154,153,834...154,302,590
G
Micos13
mitochondrial contact site and cristae organizing system subunit 13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MICOS13 mRNA
CTD
PMID:17183730
NCBI chr 9:1,439,841...1,441,782
Ensembl chr 9:1,439,058...1,442,076
G
Mis12
MIS12 kinetochore complex component
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MIS12 mRNA
CTD
PMID:17183730
NCBI chr10:55,739,741...55,747,915
Ensembl chr10:55,739,564...55,751,068
G
Mks1
MKS transition zone complex subunit 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MKS1 mRNA
CTD
PMID:17183730
NCBI chr10:72,655,921...72,667,007
Ensembl chr10:72,655,921...72,666,655
G
Mllt10
MLLT10, histone lysine methyltransferase DOT1L cofactor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MLLT10 mRNA
CTD
PMID:17183730
NCBI chr17:80,821,870...80,949,349
Ensembl chr17:80,822,556...80,949,345
G
Mmab
metabolism of cobalamin associated B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MMAB mRNA
CTD
PMID:17183730
NCBI chr12:42,159,109...42,172,518
Ensembl chr12:42,159,089...42,172,490
G
Mme
membrane metallo-endopeptidase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MME mRNA
CTD
PMID:17183730
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
G
Mmp10
matrix metallopeptidase 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MMP10 mRNA
CTD
PMID:17183730
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
G
Mmp25
matrix metallopeptidase 25
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MMP25 mRNA
CTD
PMID:17183730
NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871
G
Mpst
mercaptopyruvate sulfurtransferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MPST mRNA
CTD
PMID:17183730
NCBI chr 7:109,955,581...109,963,155
Ensembl chr 7:109,955,675...109,963,141
G
Mrnip
MRN complex interacting protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRNIP mRNA
CTD
PMID:17183730
NCBI chr10:34,501,359...34,525,474
Ensembl chr10:34,501,384...34,525,469
G
mrpl11
mitochondrial ribosomal protein L11
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL11 mRNA
CTD
PMID:17183730
NCBI chr 1:202,264,419...202,267,288
Ensembl chr 1:202,264,471...202,267,756
G
Mrpl39
mitochondrial ribosomal protein L39
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL39 mRNA
CTD
PMID:17183730
NCBI chr11:23,779,655...23,795,146
Ensembl chr11:23,779,662...23,795,125
G
Mrpl45
mitochondrial ribosomal protein L45
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL45 mRNA
CTD
PMID:17183730
NCBI chr10:82,308,650...82,320,474
Ensembl chr10:82,308,427...82,320,474
G
Mrpl53
mitochondrial ribosomal protein L53
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL53 mRNA
CTD
PMID:17183730
NCBI chr 4:115,615,329...115,616,219
G
Mrps12
mitochondrial ribosomal protein S12
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS12 mRNA
CTD
PMID:17183730
NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780
G
Mrps18a
mitochondrial ribosomal protein S18A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS18A mRNA
CTD
PMID:17183730
NCBI chr 9:14,853,322...14,869,819
Ensembl chr 9:14,853,291...14,869,835
G
Mrps24
mitochondrial ribosomal protein S24
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS24 mRNA
CTD
PMID:17183730
NCBI chr14:80,584,671...80,588,801
Ensembl chr14:80,584,673...80,588,871
G
Mrps5
mitochondrial ribosomal protein S5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS5 mRNA
CTD
PMID:17183730
NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291
G
Mrrf
mitochondrial ribosome recycling factor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRRF mRNA
CTD
PMID:17183730
NCBI chr 3:19,487,124...19,543,911
Ensembl chr 3:19,487,182...19,543,908
G
Mta3
metastasis associated 1 family, member 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MTA3 mRNA
CTD
PMID:17183730
NCBI chr 6:10,867,028...10,987,221
Ensembl chr 6:10,867,011...10,986,883
G
Mtmr4
myotubularin related protein 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MTMR4 mRNA
CTD
PMID:17183730
NCBI chr10:72,393,411...72,416,342
Ensembl chr10:72,392,551...72,416,342
G
Muc1
mucin 1, cell surface associated
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MUC1 mRNA
CTD
PMID:17183730
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
G
Mybl2
MYB proto-oncogene like 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYBL2 mRNA
CTD
PMID:17183730
NCBI chr 3:151,705,254...151,733,714
Ensembl chr 3:151,705,288...151,733,708
G
Mycbp2
MYC binding protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYCBP2 mRNA
CTD
PMID:17183730
NCBI chr15:79,937,354...80,175,432
Ensembl chr15:79,937,354...80,175,498
G
Myh7
myosin heavy chain 7
multiple interactions
EXP
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA]
CTD
PMID:16326922
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
G
Myl6b
myosin light chain 6B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYL6B mRNA
CTD
PMID:17183730
NCBI chr X:40,572,012...40,572,991
G
Myom1
myomesin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYOM1 mRNA
CTD
PMID:17183730
NCBI chr 9:110,916,156...111,039,344
Ensembl chr 9:110,915,943...111,039,344
G
Myot
myotilin
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYOT mRNA
CTD
PMID:17183730
NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841
G
Naa10
N(alpha)-acetyltransferase 10, NatA catalytic subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NAA10 mRNA
CTD
PMID:17183730
NCBI chr X:151,656,056...151,661,304
Ensembl chr X:151,656,056...151,661,252
G
Naa38
N(alpha)-acetyltransferase 38, NatC auxiliary subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NAA38 mRNA
CTD
PMID:17183730
NCBI chr10:54,117,754...54,118,913
Ensembl chr10:54,117,163...54,119,494
G
Nalcn
sodium leak channel, non-selective
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NALCN mRNA
CTD
PMID:17183730
NCBI chr15:100,398,583...100,741,243
Ensembl chr15:100,398,615...100,741,001
G
Nalf2
NALCN channel auxiliary factor 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NALF2 mRNA
CTD
PMID:17183730
NCBI chr X:64,925,100...64,951,074
Ensembl chr X:64,925,051...64,951,077
G
Nampt
nicotinamide phosphoribosyltransferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NAMPT mRNA
CTD
PMID:17183730
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
G
Nap1l1
nucleosome assembly protein 1-like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NAP1L1 mRNA
CTD
PMID:17183730
NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593
G
Nat2
N-acetyltransferase 2
increases acetylation affects metabolic processing
ISO
NAT2 protein results in increased acetylation of Hydralazine NAT2 protein affects the metabolism of Hydralazine
CTD
PMID:15627487
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
G
Nbeal1
neurobeachin-like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NBEAL1 mRNA
CTD
PMID:17183730
NCBI chr 9:61,575,154...61,743,896
Ensembl chr 9:61,575,356...61,736,750
G
Nbr1
NBR1, autophagy cargo receptor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NBR1 mRNA
CTD
PMID:17183730
NCBI chr10:86,477,775...86,506,418
Ensembl chr10:86,478,290...86,506,412
G
Ncf1
neutrophil cytosolic factor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NCF1 mRNA
CTD
PMID:17183730
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
G
Ncoa4
nuclear receptor coactivator 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NCOA4 mRNA
CTD
PMID:17183730
NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641 Ensembl chr16:7,366,542...7,409,641
G
Ncor1
nuclear receptor co-repressor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NCOR1 mRNA
CTD
PMID:17183730
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
G
Ncr1
natural cytotoxicity triggering receptor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NCR1 mRNA
CTD
PMID:17183730
NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558
G
Ndufa1
NADH:ubiquinone oxidoreductase subunit A1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA1 mRNA
CTD
PMID:17183730
NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633
G
Ndufa13
NADH:ubiquinone oxidoreductase subunit A13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA13 mRNA
CTD
PMID:17183730
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
G
Ndufa3
NADH:ubiquinone oxidoreductase subunit A3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA3 mRNA
CTD
PMID:17183730
NCBI chr 1:65,597,567...65,600,197
Ensembl chr 1:65,597,578...65,600,235
G
Ndufa5
NADH:ubiquinone oxidoreductase subunit A5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA5 mRNA
CTD
PMID:17183730
NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598
G
Ndufa6
NADH:ubiquinone oxidoreductase subunit A6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA6 mRNA
CTD
PMID:17183730
NCBI chr 7:113,866,382...113,870,239
Ensembl chr 7:113,866,382...113,870,239
G
Ndufaf6
NADH:ubiquinone oxidoreductase complex assembly factor 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFAF6 mRNA
CTD
PMID:17183730
NCBI chr 5:24,147,712...24,171,981
Ensembl chr 5:24,147,735...24,171,951
G
Ndufb1
NADH:ubiquinone oxidoreductase subunit B1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB1 mRNA
CTD
PMID:17183730
NCBI chr 6:121,115,649...121,124,055
G
Ndufb10
NADH:ubiquinone oxidoreductase subunit B10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB10 mRNA
CTD
PMID:17183730
NCBI chr10:13,749,273...13,751,434
Ensembl chr10:13,749,275...13,751,442
G
Ndufb2
NADH:ubiquinone oxidoreductase subunit B2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB2 mRNA
CTD
PMID:17183730
NCBI chr 4:68,367,526...68,374,609
Ensembl chr15:46,536,062...46,536,851 Ensembl chr 4:46,536,062...46,536,851
G
Ndufs5
NADH:ubiquinone oxidoreductase subunit S5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFS5 mRNA
CTD
PMID:17183730
NCBI chr 5:135,974,029...135,979,705
Ensembl chr 5:135,974,034...135,979,603 Ensembl chr14:135,974,034...135,979,603 Ensembl chr 2:135,974,034...135,979,603
G
Nedd1
NEDD1 gamma-tubulin ring complex targeting factor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NEDD1 mRNA
CTD
PMID:17183730
NCBI chr 7:27,233,050...27,274,486
Ensembl chr 7:27,233,316...27,274,486
G
Net1
neuroepithelial cell transforming 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NET1 mRNA
CTD
PMID:17183730
NCBI chr17:66,341,251...66,370,445
Ensembl chr17:66,340,728...66,370,441
G
Nf1
neurofibromin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NF1 mRNA
CTD
PMID:17183730
NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
G
Nfatc2
nuclear factor of activated T-cells 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NFATC2 mRNA
CTD
PMID:17183730
NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325
G
Nhlrc2
NHL repeat containing 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NHLRC2 mRNA
CTD
PMID:17183730
NCBI chr 1:255,589,743...255,648,904
Ensembl chr 1:255,589,742...255,651,408
G
Nhs
NHS actin remodeling regulator
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NHS mRNA
CTD
PMID:17183730
NCBI chr X:32,553,300...32,892,961
Ensembl chr X:32,552,026...32,889,992
G
Nmd3
NMD3 ribosome export adaptor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NMD3 mRNA
CTD
PMID:17183730
NCBI chr 2:154,012,973...154,038,466
Ensembl chr 2:154,013,020...154,039,259
G
Nme1
NME/NM23 nucleoside diphosphate kinase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NME1 mRNA
CTD
PMID:17183730
NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408
G
Nod1
nucleotide-binding oligomerization domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NOD1 mRNA
CTD
PMID:17183730
NCBI chr 4:84,060,871...84,111,668
Ensembl chr 4:84,060,880...84,111,404
G
Nos1
nitric oxide synthase 1
increases expression
EXP
Hydralazine results in increased expression of NOS1 mRNA
CTD
PMID:7533141
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
G
Nova1
NOVA alternative splicing regulator 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NOVA1 mRNA
CTD
PMID:17183730
NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289
G
Npas3
neuronal PAS domain protein 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NPAS3 mRNA
CTD
PMID:17183730
NCBI chr 6:70,702,773...71,527,928
Ensembl chr 6:70,703,170...71,524,884
G
Npdc1
neural proliferation, differentiation and control, 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NPDC1 mRNA
CTD
PMID:17183730
NCBI chr 3:8,220,446...8,226,446
Ensembl chr 3:8,213,663...8,226,866
G
Nphp4
nephrocystin 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NPHP4 mRNA
CTD
PMID:17183730
NCBI chr 5:162,986,157...163,073,708
Ensembl chr 5:162,988,370...163,073,706
G
Nppb
natriuretic peptide B
multiple interactions
EXP
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA]
CTD
PMID:16326922
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
G
Npr1
natriuretic peptide receptor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NPR1 mRNA
CTD
PMID:17183730
NCBI chr 2:175,934,181...175,950,118
Ensembl chr 2:175,934,181...175,949,505
G
Nr1h3
nuclear receptor subfamily 1, group H, member 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NR1H3 mRNA
CTD
PMID:17183730
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
G
Nr2c2
nuclear receptor subfamily 2, group C, member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NR2C2 mRNA
CTD
PMID:17183730
NCBI chr 4:124,610,216...124,666,813
Ensembl chr 4:124,608,960...124,661,902
G
Nr3c1
nuclear receptor subfamily 3, group C, member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NR3C1 mRNA
CTD
PMID:17183730
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
G
Nrep
neuronal regeneration related protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NREP mRNA
CTD
PMID:17183730
NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
G
Nrxn2
neurexin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NRXN2 mRNA
CTD
PMID:17183730
NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
G
Nsdhl
NAD(P) dependent steroid dehydrogenase-like
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NSDHL mRNA
CTD
PMID:17183730
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
G
Nsfl1c
NSFL1 cofactor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NSFL1C mRNA
CTD
PMID:17183730
NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870
G
Nsun4
NOP2/Sun RNA methyltransferase 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NSUN4 mRNA
CTD
PMID:17183730
NCBI chr 5:129,511,224...129,532,498
Ensembl chr 5:129,512,307...129,532,423 Ensembl chr 5:129,512,307...129,532,423
G
Ntan1
N-terminal asparagine amidase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NTAN1 mRNA
CTD
PMID:17183730
NCBI chr10:2,111,090...2,126,119
G
Ntsr2
neurotensin receptor 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NTSR2 mRNA
CTD
PMID:17183730
NCBI chr 6:39,424,297...39,431,015
Ensembl chr 6:39,424,324...39,431,014
G
Nudc
nuclear distribution C, dynein complex regulator
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NUDC mRNA
CTD
PMID:17183730
NCBI chr 5:145,758,006...145,771,390
Ensembl chr 5:145,758,002...145,771,425
G
Nudt7
nudix hydrolase 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NUDT7 mRNA
CTD
PMID:17183730
NCBI chr19:42,125,679...42,151,198
Ensembl chr19:42,125,711...42,151,081
G
Numb
NUMB, endocytic adaptor protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NUMB mRNA
CTD
PMID:17183730
NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
G
Nup153
nucleoporin 153
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NUP153 mRNA
CTD
PMID:17183730
NCBI chr17:17,972,217...18,024,876
Ensembl chr17:17,972,217...18,024,876
G
Nupr1
nuclear protein 1, transcriptional regulator
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NUPR1 mRNA
CTD
PMID:17183730
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
G
Nxph3
neurexophilin 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of NXPH3 mRNA
CTD
PMID:17183730
NCBI chr10:80,456,283...80,459,949
Ensembl chr10:80,455,429...80,462,415
G
Oaz1
ornithine decarboxylase antizyme 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of OAZ1 mRNA
CTD
PMID:17183730
NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310
G
Obscn
obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of OBSCN mRNA
CTD
PMID:17183730
NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723
G
Ociad2
OCIA domain containing 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of OCIAD2 mRNA
CTD
PMID:17183730
NCBI chr14:34,873,668...34,889,276
Ensembl chr14:34,873,820...34,889,265
G
Ofcc1
orofacial cleft 1 candidate 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of OFCC1 mRNA
CTD
PMID:17183730
NCBI chr17:24,506,919...24,813,225
Ensembl chr17:24,539,047...24,811,079
G
Oga
O-GlcNAcase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of OGA mRNA
CTD
PMID:17183730
NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359
G
Ogg1
8-oxoguanine DNA glycosylase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of OGG1 mRNA
CTD
PMID:17183730
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
G
Ogt
O-linked N-acetylglucosamine (GlcNAc) transferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of OGT mRNA
CTD
PMID:17183730
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
G
Opa1
OPA1, mitochondrial dynamin like GTPase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of OPA1 mRNA
CTD
PMID:17183730
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
G
Oprd1
opioid receptor, delta 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of OPRD1 mRNA
CTD
PMID:17183730
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
G
Or9i1b
olfactory receptor family 9 subfamily I member 1B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of OR9I1 mRNA
CTD
PMID:17183730
NCBI chr 1:211,096,191...211,097,141
Ensembl chr 1:211,090,402...211,097,815
G
P2rx3
purinergic receptor P2X 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of P2RX3 mRNA
CTD
PMID:17183730
NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
G
Pabpc1l2b
poly(A) binding protein cytoplasmic 1 like 2B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PABPC1L2B mRNA
CTD
PMID:17183730
G
Pafah1b3
platelet-activating factor acetylhydrolase 1b, catalytic subunit 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PAFAH1B3 mRNA
CTD
PMID:17183730
NCBI chr 1:80,881,263...80,883,789
Ensembl chr 1:80,881,309...80,883,893
G
Park7
Parkinsonism associated deglycase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PARK7 mRNA
CTD
PMID:17183730
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
G
Parp1
poly (ADP-ribose) polymerase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PARP1 mRNA
CTD
PMID:17183730
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
G
Parp14
poly (ADP-ribose) polymerase family, member 14
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PARP14 mRNA
CTD
PMID:17183730
NCBI chr11:64,902,848...64,934,916
Ensembl chr11:64,902,785...64,934,916
G
Pasd1
PAS domain containing repressor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PASD1 mRNA
CTD
PMID:17183730
NCBI chr X:149,617,933...149,639,214
Ensembl chr X:149,620,972...149,638,675
G
Pbx2
PBX homeobox 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PBX2 mRNA
CTD
PMID:17183730
NCBI chr20:4,151,500...4,156,425
Ensembl chr20:4,151,500...4,156,425
G
Pcbd1
pterin-4 alpha-carbinolamine dehydratase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PCBD1 mRNA
CTD
PMID:17183730
NCBI chr20:29,037,545...29,044,322
Ensembl chr20:28,953,864...29,044,292 Ensembl chr20:28,953,864...29,044,292
G
Pccb
propionyl-CoA carboxylase subunit beta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PCCB mRNA
CTD
PMID:17183730
NCBI chr 8:101,591,218...101,641,213
Ensembl chr 8:101,590,737...101,641,234
G
Pcdh15
protocadherin related 15
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PCDH15 mRNA
CTD
PMID:17183730
NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719
G
Pcna
proliferating cell nuclear antigen
multiple interactions
EXP
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of PCNA protein
CTD
PMID:11318962
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
G
Pdgfrb
platelet derived growth factor receptor beta
decreases expression
EXP
hydralazine decreases expression of Pdgfrb protein in liver
RGD
PMID:33315911
RGD:407420266
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
G
Pebp4
phosphatidylethanolamine binding protein 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PEBP4 mRNA
CTD
PMID:17183730
NCBI chr15:44,920,946...45,134,188
Ensembl chr15:44,921,886...45,134,191
G
Pfkfb4
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PFKFB4 mRNA
CTD
PMID:17183730
NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634
G
Pfn1
profilin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PFN1 mRNA
CTD
PMID:17183730
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
G
Pgam2
phosphoglycerate mutase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PGAM2 mRNA
CTD
PMID:17183730
NCBI chr14:80,681,796...80,683,907
Ensembl chr14:80,681,776...80,683,940
G
Pgm1
phosphoglucomutase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PGM1 mRNA
CTD
PMID:17183730
NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728
G
Phb1
prohibitin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PHB1 mRNA
CTD
PMID:17183730
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
G
Phc1
polyhomeotic homolog 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of PHC1 mRNA
CTD
PMID:17183730
NCBI chr 4:155,510,274...155,532,636
Ensembl chr 4:155,510,274...155,533,959
G
Phc2
polyhomeotic homolog 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PHC2 mRNA
CTD
PMID:17183730
NCBI chr 5:141,000,604...141,099,268
Ensembl chr 5:141,050,842...141,099,268
G
Phf24
PHD finger protein 24
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PHF24 mRNA
CTD
PMID:17183730
NCBI chr 5:57,143,428...57,171,054
Ensembl chr 5:57,142,632...57,168,497
G
Pigs
phosphatidylinositol glycan anchor biosynthesis, class S
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PIGS mRNA
CTD
PMID:17183730
NCBI chr10:63,222,611...63,237,190
Ensembl chr10:63,222,572...63,237,187
G
Pip
prolactin induced protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PIP mRNA
CTD
PMID:17183730
NCBI chr 4:70,787,627...70,791,921
Ensembl chr 4:70,787,627...70,791,921
G
Plcg1
phospholipase C, gamma 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PLCG1 mRNA
CTD
PMID:17183730
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
G
Plrg1
pleiotropic regulator 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PLRG1 mRNA
CTD
PMID:17183730
NCBI chr 2:168,408,139...168,424,470
Ensembl chr 2:168,408,124...168,424,522
G
Plxdc1
plexin domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PLXDC1 mRNA
CTD
PMID:17183730
NCBI chr10:82,922,499...82,982,124
Ensembl chr10:82,922,508...82,982,130
G
Pmm2
phosphomannomutase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PMM2 mRNA
CTD
PMID:17183730
NCBI chr10:6,961,521...6,982,913
Ensembl chr10:6,961,709...6,983,098
G
Pmvk
phosphomevalonate kinase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PMVK mRNA
CTD
PMID:17183730
NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364
G
Pole4
DNA polymerase epsilon 4, accessory subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of POLE4 mRNA
CTD
PMID:17183730
NCBI chr 4:115,165,285...115,171,097
Ensembl chr 4:115,165,285...115,171,097
G
Polr1has
RNA polymerase I subunit H, antisense
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of POLR1HASP mRNA
CTD
PMID:17183730
NCBI chr 9:16,098,624...16,099,790
Ensembl chr 9:16,098,624...16,099,790
G
Polr2l
RNA polymerase II, I and III subunit L
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of POLR2L mRNA
CTD
PMID:17183730
NCBI chr 1:196,570,051...196,572,060
G
Pop5
POP5 homolog, ribonuclease P/MRP subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of POP5 mRNA
CTD
PMID:17183730
NCBI chr12:41,376,755...41,384,882
Ensembl chr12:41,376,755...41,381,336
G
Ppil4
peptidylprolyl isomerase like 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PPIL4 mRNA
CTD
PMID:17183730
NCBI chr 1:2,273,582...2,305,639
Ensembl chr 1:2,273,609...2,305,632
G
Ppp1r12a
protein phosphatase 1, regulatory subunit 12A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP1R12A mRNA
CTD
PMID:17183730
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
G
Ppp1r9a
protein phosphatase 1, regulatory subunit 9A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP1R9A mRNA
CTD
PMID:17183730
NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907
G
Ppp2r1b
protein phosphatase 2 scaffold subunit A beta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP2R1B mRNA
CTD
PMID:17183730
NCBI chr 8:51,195,860...51,228,442
Ensembl chr 8:51,186,717...51,228,485
G
Prb3
proline-rich protein BstNI subfamily 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRB3 mRNA
CTD
PMID:17183730
NCBI chr 4:165,564,424...165,569,229
Ensembl chr 4:165,564,424...165,569,227
G
Prkcsh
PRKCSH beta subunit of glucosidase II
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRKCSH mRNA
CTD
PMID:17183730
NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492
G
Prkg1
protein kinase cGMP-dependent 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRKG1 mRNA
CTD
PMID:17183730
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
G
Prom2
prominin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PROM2 mRNA
CTD
PMID:17183730
NCBI chr 3:114,747,654...114,761,787
Ensembl chr 3:114,747,654...114,761,787
G
Prpf18
pre-mRNA processing factor 18
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRPF18 mRNA
CTD
PMID:17183730
NCBI chr17:73,630,560...73,661,210
Ensembl chr17:73,630,571...73,690,979
G
Prr13
proline rich 13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRR13 mRNA
CTD
PMID:17183730
NCBI chr 7:133,592,511...133,595,817
Ensembl chr 7:133,592,490...133,601,005
G
Prtfdc1
phosphoribosyl transferase domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRTFDC1 mRNA
CTD
PMID:17183730
NCBI chr17:83,549,608...83,654,517
Ensembl chr17:83,548,803...83,655,179
G
Psd3
pleckstrin and Sec7 domain containing 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSD3 mRNA
CTD
PMID:17183730
NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547
G
Psma2
proteasome 20S subunit alpha 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMA2 mRNA
CTD
PMID:17183730
NCBI chr17:50,554,536...50,564,923
Ensembl chr17:50,551,924...50,564,938
G
Psma4
proteasome 20S subunit alpha 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMA4 mRNA
CTD
PMID:17183730
NCBI chr 8:55,340,431...55,347,893
Ensembl chr 8:55,340,386...55,347,890
G
Psmb1
proteasome 20S subunit beta 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB1 mRNA
CTD
PMID:17183730
NCBI chr 1:56,442,432...56,463,544
Ensembl chr 1:56,420,618...56,463,560
G
Psmb2
proteasome 20S subunit beta 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB2 mRNA
CTD
PMID:17183730
NCBI chr 5:138,970,564...139,002,715
Ensembl chr 5:138,970,533...139,021,137
G
Psmb3
proteasome 20S subunit beta 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB3 mRNA
CTD
PMID:17183730
NCBI chr10:82,697,425...82,704,521
Ensembl chr10:82,697,425...82,704,521
G
Psmb6
proteasome 20S subunit beta 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB6 mRNA
CTD
PMID:17183730
NCBI chr10:55,239,256...55,241,586
Ensembl chr10:55,239,241...55,241,586
G
Psmb9
proteasome 20S subunit beta 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB9 mRNA
CTD
PMID:17183730
NCBI chr20:4,667,044...4,672,512
Ensembl chr20:4,666,046...4,672,512
G
Psmc6
proteasome 26S subunit, ATPase 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMC6 mRNA
CTD
PMID:17183730
NCBI chr15:18,542,585...18,564,057
Ensembl chr15:18,542,563...18,564,055
G
Psmd1
proteasome 26S subunit, non-ATPase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD1 mRNA
CTD
PMID:17183730
NCBI chr 9:86,709,714...86,785,213
Ensembl chr 9:86,709,947...86,785,211
G
Psmd3
proteasome 26S subunit, non-ATPase 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of PSMD3 mRNA
CTD
PMID:17183730
NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618
G
Psmd4
proteasome 26S subunit ubiquitin receptor, non-ATPase 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD4 mRNA
CTD
PMID:17183730
NCBI chr 2:182,598,934...182,608,250
Ensembl chr 2:182,598,934...182,608,194
G
Psmd8
proteasome 26S subunit, non-ATPase 8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD8 mRNA
CTD
PMID:17183730
NCBI chr 1:84,474,377...84,481,209
Ensembl chr 1:84,474,378...84,481,209
G
Psmg3
proteasome assembly chaperone 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMG3 mRNA
CTD
PMID:17183730
NCBI chr12:14,809,440...14,812,357
Ensembl chr12:14,809,450...14,812,342
G
Ptk2b
protein tyrosine kinase 2 beta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PTK2B mRNA
CTD
PMID:17183730
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
G
Ptma
prothymosin alpha
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PTMA mRNA
CTD
PMID:17183730
NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333
G
Ptprj
protein tyrosine phosphatase, receptor type, J
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PTPRJ mRNA
CTD
PMID:17183730
NCBI chr 3:76,405,917...76,561,842
Ensembl chr 3:76,405,927...76,562,260
G
Puf60
poly-U binding splicing factor 60
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PUF60 mRNA
CTD
PMID:17183730
NCBI chr 7:107,782,799...107,793,759
Ensembl chr 7:107,782,770...107,794,531
G
Pum1
pumilio RNA-binding family member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PUM1 mRNA
CTD
PMID:17183730
NCBI chr 5:142,836,933...142,954,331
Ensembl chr 5:142,837,127...142,954,039
G
Pycard
PYD and CARD domain containing
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PYCARD mRNA
CTD
PMID:17183730
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
G
Pycr3
pyrroline-5-carboxylate reductase 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of PYCR3 mRNA
CTD
PMID:17183730
NCBI chr 7:107,603,543...107,608,831
Ensembl chr 7:107,581,930...107,608,799
G
Rab13
RAB13, member RAS oncogene family
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB13 mRNA
CTD
PMID:17183730
NCBI chr 2:175,674,894...175,680,043
Ensembl chr 2:175,675,005...175,680,036
G
Rab1a
RAB1A, member RAS oncogene family
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB1A mRNA
CTD
PMID:17183730
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
G
Rab30
RAB30, member RAS oncogene family
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB30 mRNA
CTD
PMID:17183730
NCBI chr 1:146,803,719...146,898,369
Ensembl chr 1:146,803,714...146,892,181
G
Rab3a
RAB3A, member RAS oncogene family
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3A mRNA
CTD
PMID:17183730
NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336
G
Rab3d
RAB3D, member RAS oncogene family
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3D mRNA
CTD
PMID:17183730
NCBI chr 8:20,438,622...20,449,269
Ensembl chr 8:20,439,294...20,449,185
G
Rab6a
RAB6A, member RAS oncogene family
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB6A mRNA
CTD
PMID:17183730
NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715
G
Rabep2
rabaptin, RAB GTPase binding effector protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RABEP2 mRNA
CTD
PMID:17183730
NCBI chr 1:181,010,305...181,026,651
Ensembl chr 1:181,010,305...181,026,648
G
Rabgef1
RAB guanine nucleotide exchange factor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RABGEF1 mRNA
CTD
PMID:17183730
NCBI chr12:26,459,190...26,503,790
Ensembl chr12:26,460,175...26,503,744
G
Rad21
RAD21 cohesin complex component
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAD21 mRNA
CTD
PMID:17183730
NCBI chr 7:83,287,867...83,314,810
Ensembl chr 7:83,287,870...83,314,817
G
Ralgds
ral guanine nucleotide dissociation stimulator
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RALGDS mRNA
CTD
PMID:17183730
NCBI chr 3:11,839,686...11,880,059
Ensembl chr 3:11,839,416...11,880,059
G
Ralgps1
Ral GEF with PH domain and SH3 binding motif 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RALGPS1 mRNA
CTD
PMID:17183730
NCBI chr 3:16,433,323...16,670,276
Ensembl chr 3:16,433,742...16,669,972
G
Ramp2
receptor activity modifying protein 2
multiple interactions
EXP
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein]
CTD
PMID:16326922
NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,188,812...86,231,829
G
Ramp3
receptor activity modifying protein 3
multiple interactions
EXP
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein]
CTD
PMID:16326922
NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902
G
Rap1a
RAP1A, member of RAS oncogene family
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAP1A mRNA
CTD
PMID:17183730
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
G
Rarb
retinoic acid receptor, beta
decreases methylation
ISO
Hydralazine results in decreased methylation of RARB promoter
CTD
PMID:15862127
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
G
Rbl1
RB transcriptional corepressor like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RBL1 mRNA
CTD
PMID:17183730
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
G
Rbm22
RNA binding motif protein 22
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RBM22 mRNA
CTD
PMID:17183730
NCBI chr18:54,013,374...54,024,182
Ensembl chr18:54,013,351...54,024,569
G
Rbm4
RNA binding motif protein 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RBM4 mRNA
CTD
PMID:17183730
NCBI chr 1:202,078,442...202,087,506
Ensembl chr 1:202,085,279...202,105,380
G
Rcl1
RNA terminal phosphate cyclase-like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RCL1 mRNA
CTD
PMID:17183730
NCBI chr 1:226,824,561...226,869,046
Ensembl chr 1:226,824,534...226,902,315
G
Reep4
receptor accessory protein 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of REEP4 mRNA
CTD
PMID:17183730
NCBI chr15:45,620,317...45,623,524
Ensembl chr15:45,619,941...45,623,526
G
Reg1a
regenerating family member 1 alpha
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of REG1A mRNA
CTD
PMID:17183730
NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570
G
Rela
RELA proto-oncogene, NF-kB subunit
multiple interactions
ISO
Hydralazine inhibits the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]
CTD
PMID:27238871
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Ren
renin
multiple interactions increases activity increases expression
ISO EXP
Alprenolol inhibits the reaction [Hydralazine results in increased expression of REN protein] Hydralazine results in increased activity of REN protein
CTD
PMID:231700 PMID:923630 PMID:2203898 PMID:2953239 PMID:3154321
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
G
Rer1
retention in endoplasmic reticulum sorting receptor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RER1 mRNA
CTD
PMID:17183730
NCBI chr 5:165,634,567...165,646,643
Ensembl chr 5:165,634,300...165,646,750
G
Rfx1
regulatory factor X1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RFX1 mRNA
CTD
PMID:17183730
NCBI chr19:24,061,336...24,092,044
Ensembl chr19:24,061,336...24,092,044
G
Rgs7bp
regulator of G-protein signaling 7 binding protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS7BP mRNA
CTD
PMID:17183730
NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505
G
Rgs9
regulator of G-protein signaling 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS9 mRNA
CTD
PMID:17183730
NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892
G
Rgs9bp
regulator of G protein signaling 9 binding protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS9BP mRNA
CTD
PMID:17183730
NCBI chr 1:88,249,438...88,250,151
Ensembl chr 1:88,249,438...88,250,151
G
Rin3
Ras and Rab interactor 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RIN3 mRNA
CTD
PMID:17183730
NCBI chr 6:121,431,776...121,540,956
Ensembl chr 6:121,431,339...121,540,957
G
Rinl
Ras and Rab interactor-like
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RINL mRNA
CTD
PMID:17183730
NCBI chr 1:84,077,011...84,088,590
Ensembl chr 1:84,077,265...84,088,330
G
Ripk1
receptor interacting serine/threonine kinase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RIPK1 mRNA
CTD
PMID:17183730
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
G
Ripply1
ripply transcriptional repressor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RIPPLY1 mRNA
CTD
PMID:17183730
NCBI chr X:103,436,731...103,440,904
Ensembl chr X:103,436,729...103,443,349
G
Rmnd5b
required for meiotic nuclear division 5 homolog B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RMND5B mRNA
CTD
PMID:17183730
NCBI chr10:35,881,250...35,892,322
Ensembl chr10:35,881,268...35,892,265
G
Rnf152
ring finger protein 152
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RNF152 mRNA
CTD
PMID:17183730
NCBI chr13:21,324,039...21,403,405
Ensembl chr13:21,323,824...21,403,113
G
Rnf187
ring finger protein 187
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RNF187 mRNA
CTD
PMID:17183730
NCBI chr10:43,709,493...43,715,392
Ensembl chr10:43,702,357...43,716,157
G
Robo2
roundabout guidance receptor 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ROBO2 mRNA
CTD
PMID:17183730
NCBI chr11:12,528,949...14,096,726
Ensembl chr11:12,528,951...13,041,536
G
Romo1
reactive oxygen species modulator 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ROMO1 mRNA
CTD
PMID:17183730
NCBI chr 3:144,659,709...144,661,310
Ensembl chr 3:144,659,826...144,661,310
G
Rpl10a
ribosomal protein L10A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL10A mRNA
CTD
PMID:17183730
NCBI chr20:6,388,800...6,391,358
Ensembl chr20:6,385,823...6,391,357
G
Rpl13
ribosomal protein L13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL13 mRNA
CTD
PMID:17183730
NCBI chr19:51,153,990...51,156,541
Ensembl chr19:51,153,924...51,163,014
G
Rpl17
ribosomal protein L17
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL17 mRNA
CTD
PMID:17183730
NCBI chr18:68,581,141...68,584,253
Ensembl chr18:68,581,098...68,584,253
G
Rpl18a
ribosomal protein L18A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL18A mRNA
CTD
PMID:17183730
NCBI chr16:18,542,555...18,544,578
Ensembl chr16:18,542,566...18,545,546
G
Rpl23a
ribosomal protein L23A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL23A mRNA
CTD
PMID:17183730
NCBI chr10:63,076,660...63,079,346
Ensembl chr10:63,076,066...63,079,346
G
Rpl24
ribosomal protein L24
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL24 mRNA
CTD
PMID:17183730
NCBI chr11:44,653,937...44,659,346
Ensembl chr11:44,653,937...44,659,370
G
Rpl26
ribosomal protein L26
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL26 mRNA
CTD
PMID:17183730
NCBI chr10:53,610,836...53,613,966
Ensembl chr10:53,610,421...53,613,966
G
Rpl27
ribosomal protein L27
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL27 mRNA
CTD
PMID:17183730
NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193
G
Rpl31
ribosomal protein L31
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL31 mRNA
CTD
PMID:17183730
NCBI chr 9:41,647,397...41,651,441
Ensembl chr 9:41,647,426...41,662,129
G
Rpl34
ribosomal protein L34
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL34 mRNA
CTD
PMID:17183730
NCBI chr 2:219,284,373...219,288,108
Ensembl chr 2:219,284,382...219,288,111
G
Rpl36
ribosomal protein L36
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL36 mRNA
CTD
PMID:17183730
NCBI chr 9:1,441,986...1,447,397
Ensembl chr 6:98,809,534...98,809,897
G
Rpl37a
ribosomal protein L37A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL37A mRNA
CTD
PMID:17183730
NCBI chr 9:74,298,843...74,300,926
G
Rpl39
ribosomal protein L39
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL39 mRNA
CTD
PMID:17183730
NCBI chr X:116,327,216...116,330,211
Ensembl chr18:6,326,330...6,326,692 Ensembl chr X:6,326,330...6,326,692
G
Rpl41
ribosomal protein L41
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL41 mRNA
CTD
PMID:17183730
NCBI chr 7:977,885...978,965
G
Rpl7
ribosomal protein L7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL7 mRNA
CTD
PMID:17183730
NCBI chr 5:3,217,184...3,220,192
G
Rplp1
ribosomal protein lateral stalk subunit P1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPLP1 mRNA
CTD
PMID:17183730
NCBI chr 8:62,394,008...62,395,341
Ensembl chr 8:62,393,177...62,395,339
G
Rpp21
ribonuclease P/MRP subunit p21
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPP21 mRNA
CTD
PMID:17183730
NCBI chr20:2,018,170...2,020,100
Ensembl chr20:2,018,147...2,020,106
G
Rps11
ribosomal protein S11
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS11 mRNA
CTD
PMID:17183730
NCBI chr 1:95,605,690...95,607,798
Ensembl chr 1:95,605,692...95,607,874
G
Rps12
ribosomal protein S12
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS12 mRNA
CTD
PMID:17183730
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
G
Rps19bp1
ribosomal protein S19 binding protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS19BP1 mRNA
CTD
PMID:17183730
NCBI chr 7:111,809,354...111,812,741
Ensembl chr 7:111,809,355...111,812,757
G
Rps2
ribosomal protein S2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS2 mRNA
CTD
PMID:17183730
NCBI chr10:13,747,316...13,749,165
Ensembl chr10:13,747,301...13,749,163
G
Rps27
ribosomal protein S27
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS27 mRNA
CTD
PMID:17183730
NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964
G
Rps27a
ribosomal protein S27a
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS27A mRNA
CTD
PMID:17183730
NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011 Ensembl chr 5:103,285,734...103,288,011
G
Rps6ka5
ribosomal protein S6 kinase A5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS6KA5 mRNA
CTD
PMID:17183730
NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224
G
Rps9
ribosomal protein S9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS9 mRNA
CTD
PMID:17183730
NCBI chr 1:65,511,723...65,515,076
Ensembl chr 1:65,511,723...65,515,123
G
Rspo4
R-spondin 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RSPO4 mRNA
CTD
PMID:17183730
NCBI chr 3:140,357,256...140,391,780
Ensembl chr 3:140,357,424...140,388,254
G
Rsrp1
arginine and serine rich protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RSRP1 mRNA
CTD
PMID:17183730
NCBI chr 5:147,147,774...147,151,523
Ensembl chr 5:147,147,784...147,151,523
G
RT1-CE16
RT1 class I, locus CE16
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-A mRNA
CTD
PMID:17183730
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
G
RT1-DOb
RT1 class II, locus DOb
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-DOB mRNA
CTD
PMID:17183730
NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667
G
Rtn4rl1
reticulon 4 receptor-like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RTN4RL1 mRNA
CTD
PMID:17183730
NCBI chr10:60,043,246...60,116,977
Ensembl chr10:60,043,002...60,116,978
G
Rwdd1
RWD domain containing 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RWDD1 mRNA
CTD
PMID:17183730
NCBI chr20:25,949,723...25,967,147
Ensembl chr20:25,941,966...25,967,193
G
Rxrg
retinoid X receptor gamma
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of RXRG mRNA
CTD
PMID:17183730
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
G
S100a6
S100 calcium binding protein A6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of S100A6 mRNA
CTD
PMID:17183730
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
G
S100a8
S100 calcium binding protein A8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of S100A8 mRNA
CTD
PMID:17183730
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
G
S100pbp
S100P binding protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of S100PBP mRNA
CTD
PMID:17183730
NCBI chr 5:141,494,352...141,535,752
Ensembl chr 5:141,494,353...141,535,525
G
Samd4a
sterile alpha motif domain containing 4A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SAMD4A mRNA
CTD
PMID:17183730
NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380
G
Samm50
SAMM50 sorting and assembly machinery component
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SAMM50 mRNA
CTD
PMID:17183730
NCBI chr 7:115,317,472...115,341,682
Ensembl chr 7:115,317,404...115,341,682
G
Saraf
store-operated calcium entry-associated regulatory factor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SARAF mRNA
CTD
PMID:17183730
NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545
G
Scap
SREBF chaperone
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SCAP mRNA
CTD
PMID:17183730
NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666
G
Scarf1
scavenger receptor class F, member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SCARF1 mRNA
CTD
PMID:17183730
NCBI chr10:60,359,213...60,371,516
Ensembl chr10:60,359,197...60,371,516
G
Scml1
Scm polycomb group protein like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SCML1 mRNA
CTD
PMID:17183730
NCBI chr X:32,893,100...32,912,686
Ensembl chr X:32,894,327...32,911,366
G
Scnn1b
sodium channel epithelial 1 subunit beta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SCNN1B mRNA
CTD
PMID:17183730
NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451
G
Scrn2
secernin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SCRN2 mRNA
CTD
PMID:17183730
NCBI chr10:82,016,604...82,020,676
Ensembl chr10:82,016,649...82,020,675
G
Sdf2l1
stromal cell-derived factor 2-like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SDF2L1 mRNA
CTD
PMID:17183730
NCBI chr11:83,872,659...83,874,902
Ensembl chr11:83,872,659...83,874,902
G
Sdhaf3
succinate dehydrogenase complex assembly factor 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SDHAF3 mRNA
CTD
PMID:17183730
NCBI chr 4:35,100,533...35,160,740
Ensembl chr 4:35,100,506...35,160,749
G
Sec11c
SEC11 homolog C, signal peptidase complex subunit
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SEC11C mRNA
CTD
PMID:17183730
NCBI chr18:59,320,932...59,337,272
Ensembl chr18:59,320,884...59,337,364
G
Sec31a
SEC31 homolog A, COPII coat complex component
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SEC31A mRNA
CTD
PMID:17183730
NCBI chr14:9,214,324...9,269,281
Ensembl chr14:9,214,349...9,269,273
G
Selenow
selenoprotein W
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SELENOW mRNA
CTD
PMID:17183730
NCBI chr 1:76,599,441...76,604,514
Ensembl chr 1:76,598,779...76,604,724 Ensembl chr 1:76,598,779...76,604,724
G
Selplg
selectin P ligand
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SELPLG mRNA
CTD
PMID:17183730
NCBI chr12:42,796,690...42,809,908
Ensembl chr12:42,796,580...42,812,585
G
Sema4a
semaphorin 4A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SEMA4A mRNA
CTD
PMID:17183730
NCBI chr 2:173,896,432...173,917,903
Ensembl chr 2:173,896,439...173,914,442
G
Septin2
septin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SEPTIN2 mRNA
CTD
PMID:17183730
NCBI chr 9:94,018,141...94,051,386
Ensembl chr 9:94,018,208...94,051,386
G
Serp2
stress-associated endoplasmic reticulum protein family member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SERP2 mRNA
CTD
PMID:17183730
NCBI chr15:51,879,882...51,903,958
Ensembl chr15:51,879,877...51,904,785
G
Serpine1
serpin family E member 1
multiple interactions decreases expression
EXP
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 mRNA; [troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 protein Hydralazine results in decreased expression of SERPINE1 mRNA
CTD
PMID:11318962 PMID:23415681
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
G
Serping1
serpin family G member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SERPING1 mRNA
CTD
PMID:17183730
NCBI chr 3:69,842,726...69,852,583
Ensembl chr 3:69,842,739...69,852,034
G
Sertad2
SERTA domain containing 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SERTAD2 mRNA
CTD
PMID:17183730
NCBI chr14:94,733,637...94,838,200
Ensembl chr14:94,733,579...94,838,313
G
Sf1
splicing factor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SF1 mRNA
CTD
PMID:17183730
NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330
G
Sf3b6
splicing factor 3B, subunit 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SF3B6 mRNA
CTD
PMID:17183730
NCBI chr 6:27,826,044...27,835,086
Ensembl chr 6:27,826,029...27,835,156
G
Shank2
SH3 and multiple ankyrin repeat domains 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SHANK2 mRNA
CTD
PMID:17183730
NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394
G
Shisa2
shisa family member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SHISA2 mRNA
CTD
PMID:17183730
NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013
G
Shoc1
shortage in chiasmata 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SHOC1 mRNA
CTD
PMID:17183730
NCBI chr 5:73,864,423...73,956,487
Ensembl chr 5:73,866,334...73,956,444
G
Shox2
SHOX homeobox 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SHOX2 mRNA
CTD
PMID:17183730
NCBI chr 2:151,217,049...151,227,180
Ensembl chr 2:151,217,552...151,227,143
G
Sidt2
SID1 transmembrane family, member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SIDT2 mRNA
CTD
PMID:17183730
NCBI chr 8:46,232,379...46,248,913
Ensembl chr 8:46,232,383...46,248,700
G
Sipa1l1
signal-induced proliferation-associated 1 like 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SIPA1L1 mRNA
CTD
PMID:17183730
NCBI chr 6:101,839,351...102,118,408
Ensembl chr 6:101,839,404...102,116,950
G
Ski
Ski proto-oncogene
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SKI mRNA
CTD
PMID:17183730
NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733
G
Slc12a3
solute carrier family 12 member 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC12A3 mRNA
CTD
PMID:17183730
NCBI chr19:10,630,651...10,679,250
Ensembl chr19:10,631,393...10,669,091
G
Slc16a2
solute carrier family 16 member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC16A2 mRNA
CTD
PMID:17183730
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
G
Slc17a9
solute carrier family 17 member 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC17A9 mRNA
CTD
PMID:17183730
NCBI chr 3:167,839,246...167,857,462
Ensembl chr 3:167,839,385...167,855,985
G
Slc19a2
solute carrier family 19 member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC19A2 mRNA
CTD
PMID:17183730
NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172
G
Slc22a16
solute carrier family 22 member 16
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC22A16 mRNA
CTD
PMID:17183730
NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019
G
Slc22a17
solute carrier family 22, member 17
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC22A17 mRNA
CTD
PMID:17183730
NCBI chr15:28,382,285...28,389,435
Ensembl chr15:28,382,292...28,388,799
G
Slc22a2
solute carrier family 22 member 2
multiple interactions
ISO
Hydralazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
CTD
PMID:21599003
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
G
Slc23a3
solute carrier family 23, member 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC23A3 mRNA
CTD
PMID:17183730
NCBI chr 9:76,622,621...76,633,188
Ensembl chr 9:76,622,800...76,631,366
G
Slc25a13
solute carrier family 25 member 13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC25A13 mRNA
CTD
PMID:17183730
NCBI chr 4:34,179,224...34,361,912
Ensembl chr 4:34,179,224...34,361,902
G
Slc25a5
solute carrier family 25 member 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC25A5 mRNA
CTD
PMID:17183730
NCBI chr X:116,031,896...116,034,963
Ensembl chr X:116,031,803...116,034,967
G
Slc2a9
solute carrier family 2 member 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC2A9 mRNA
CTD
PMID:17183730
NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981
G
Slc30a2
solute carrier family 30 member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC30A2 mRNA
CTD
PMID:17183730
NCBI chr 5:146,559,733...146,571,957
Ensembl chr 5:146,559,733...146,571,956
G
Slc35c1
solute carrier family 35 member C1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC35C1 mRNA
CTD
PMID:17183730
NCBI chr 3:78,421,925...78,429,603
Ensembl chr 3:78,421,933...78,428,520
G
Slc3a2
solute carrier family 3 member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC3A2 mRNA
CTD
PMID:17183730
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
G
Slc6a13
solute carrier family 6 member 13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A13 mRNA
CTD
PMID:17183730
NCBI chr 4:154,539,246...154,577,784
Ensembl chr 4:154,540,468...154,576,152
G
Slc6a2
solute carrier family 6 member 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A2 mRNA
CTD
PMID:17183730
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
G
Slc8b1
solute carrier family 8 member B1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC8B1 mRNA
CTD
PMID:17183730
NCBI chr12:36,029,759...36,053,087
Ensembl chr12:36,029,760...36,053,031
G
Slirp
SRA stem-loop interacting RNA binding protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLIRP mRNA
CTD
PMID:17183730
NCBI chr 6:107,088,760...107,097,791
Ensembl chr 6:107,088,403...107,097,791
G
Smarcc1
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SMARCC1 mRNA
CTD
PMID:17183730
NCBI chr 8:110,111,097...110,214,734
Ensembl chr 8:110,111,122...110,214,720
G
Smo
smoothened, frizzled class receptor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SMO mRNA
CTD
PMID:17183730
NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
G
Smurf2
SMAD specific E3 ubiquitin protein ligase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SMURF2 mRNA
CTD
PMID:17183730
NCBI chr10:91,761,798...91,862,485
Ensembl chr10:91,761,807...91,862,488
G
Snai3
snail family transcriptional repressor 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNAI3 mRNA
CTD
PMID:17183730
NCBI chr19:50,516,771...50,529,295
Ensembl chr19:50,516,771...50,523,486
G
Snf8
SNF8 subunit of ESCRT-II
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNF8 mRNA
CTD
PMID:17183730
NCBI chr10:80,984,337...80,996,724
Ensembl chr10:80,984,363...80,996,734
G
Snrnp70
small nuclear ribonucleoprotein U1 subunit 70
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRNP70 mRNA
CTD
PMID:17183730
NCBI chr 1:95,856,038...95,876,434
Ensembl chr 1:95,856,036...95,876,392
G
Snrpb
small nuclear ribonucleoprotein polypeptides B and B1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPB mRNA
CTD
PMID:17183730
NCBI chr 3:117,369,816...117,379,344
Ensembl chr 3:117,370,100...117,379,339
G
Snrpb2
small nuclear ribonucleoprotein polypeptide B2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPB2 mRNA
CTD
PMID:17183730
NCBI chr 3:130,399,239...130,408,821
Ensembl chr 3:130,399,248...130,408,812
G
Snrpd2
small nuclear ribonucleoprotein D2 polypeptide
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPD2 mRNA
CTD
PMID:17183730
NCBI chr 1:78,798,377...78,801,227
Ensembl chr 1:78,798,377...78,803,351
G
Snrpg
small nuclear ribonucleoprotein polypeptide G
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPG mRNA
CTD
PMID:17183730
NCBI chr 4:118,812,278...118,819,827
Ensembl chr 4:118,812,252...118,819,826
G
Snu13
small nuclear ribonucleoprotein 13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNU13 mRNA
CTD
PMID:17183730
NCBI chr 7:113,565,293...113,570,887
Ensembl chr 7:113,565,295...113,570,872 Ensembl chr 1:113,565,295...113,570,872
G
Sox1
SRY-box transcription factor 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SOX1 mRNA
CTD
PMID:17183730
NCBI chr16:77,135,577...77,139,592
Ensembl chr16:77,137,584...77,138,762
G
Sox9
SRY-box transcription factor 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SOX9 mRNA
CTD
PMID:17183730
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
G
Spdef
SAM pointed domain containing ets transcription factor
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SPDEF mRNA
CTD
PMID:17183730
NCBI chr20:5,771,440...5,785,893
Ensembl chr20:5,771,441...5,785,893
G
Spint1
serine peptidase inhibitor, Kunitz type 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SPINT1 mRNA
CTD
PMID:17183730
NCBI chr 3:106,231,082...106,244,121
Ensembl chr 3:106,231,444...106,244,119
G
Sprr1a
small proline-rich protein 1A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SPRR1A mRNA
CTD
PMID:17183730
NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063
G
Sprr1b
small proline-rich protein 1B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SPRR1B mRNA
CTD
PMID:17183730
NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567
G
Spsb2
splA/ryanodine receptor domain and SOCS box containing 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SPSB2 mRNA
CTD
PMID:17183730
NCBI chr 4:157,613,404...157,615,293
Ensembl chr 4:157,613,401...157,615,284
G
Srp72
signal recognition particle 72
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SRP72 mRNA
CTD
PMID:17183730
NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729
G
Srp9
signal recognition particle 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SRP9 mRNA
CTD
PMID:17183730
NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
G
Srpk3
SRSF protein kinase 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SRPK3 mRNA
CTD
PMID:17183730
NCBI chr X:151,510,452...151,515,208
Ensembl chr X:151,510,539...151,515,198
G
Srxn1
sulfiredoxin 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SRXN1 mRNA
CTD
PMID:17183730
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
G
Ssbp4
single stranded DNA binding protein 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SSBP4 mRNA
CTD
PMID:17183730
NCBI chr16:18,828,014...18,838,941
Ensembl chr16:18,828,054...18,838,947
G
Sspn
sarcospan
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SSPN mRNA
CTD
PMID:17183730
NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554
G
Ssr1
signal sequence receptor subunit 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SSR1 mRNA
CTD
PMID:17183730
NCBI chr17:26,833,720...26,861,821
Ensembl chr17:26,833,741...26,861,821
G
St8sia2
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ST8SIA2 mRNA
CTD
PMID:17183730
NCBI chr 1:127,762,573...127,838,017
Ensembl chr 1:127,762,573...127,838,091
G
Stab2
stabilin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of STAB2 mRNA
CTD
PMID:17183730
NCBI chr 7:21,249,426...21,433,051
Ensembl chr 7:21,249,391...21,434,042
G
Stag1
STAG1 cohesin complex component
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of STAG1 mRNA
CTD
PMID:17183730
NCBI chr 8:101,179,039...101,564,684
Ensembl chr 8:101,179,039...101,564,677
G
Steap2
STEAP2 metalloreductase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of STEAP2 mRNA
CTD
PMID:17183730
NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791
G
Stk38
serine/threonine kinase 38
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of STK38 mRNA
CTD
PMID:17183730
NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198
G
Stx11
syntaxin 11
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of STX11 mRNA
CTD
PMID:17183730
NCBI chr 1:7,293,427...7,320,060
Ensembl chr 1:7,289,976...7,320,164
G
Stx5
syntaxin 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of STX5 mRNA
CTD
PMID:17183730
NCBI chr 1:205,637,401...205,653,563
Ensembl chr 1:205,637,413...205,653,563
G
Styx
serine/threonine/tyrosine interacting protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of STYX mRNA
CTD
PMID:17183730
NCBI chr15:18,565,214...18,595,797
Ensembl chr15:18,564,633...18,593,524
G
Sufu
SUFU negative regulator of hedgehog signaling
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SUFU mRNA
CTD
PMID:17183730
NCBI chr 1:245,257,725...245,355,576
Ensembl chr 1:245,257,768...245,355,577
G
Sumo3
small ubiquitin-like modifier 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SUMO3 mRNA
CTD
PMID:17183730
NCBI chr20:11,010,140...11,020,850
Ensembl chr20:11,007,148...11,020,877 Ensembl chr20:11,007,148...11,020,877
G
Syp
synaptophysin
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SYP mRNA
CTD
PMID:17183730
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
G
Syt6
synaptotagmin 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of SYT6 mRNA
CTD
PMID:17183730
NCBI chr 2:191,093,009...191,152,283
Ensembl chr 2:191,093,007...191,149,956
G
Tacc2
transforming, acidic coiled-coil containing protein 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TACC2 mRNA
CTD
PMID:17183730
NCBI chr 1:185,139,223...185,327,881
Ensembl chr 1:185,116,111...185,327,881
G
Taf12
TATA-box binding protein associated factor 12
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TAF12 mRNA
CTD
PMID:17183730
NCBI chr 5:144,472,816...144,490,299
Ensembl chr 5:144,472,841...144,488,849
G
Tafa1
TAFA chemokine like family member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TAFA1 mRNA
CTD
PMID:17183730
NCBI chr 4:128,738,028...129,244,223
Ensembl chr 4:128,739,313...129,243,777
G
Taldo1
transaldolase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TALDO1 mRNA
CTD
PMID:17183730
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
G
Tbc1d1
TBC1 domain family member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TBC1D1 mRNA
CTD
PMID:17183730
NCBI chr14:43,936,820...44,135,133
Ensembl chr14:43,935,636...44,136,499
G
Tbcd
tubulin folding cofactor D
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TBCD mRNA
CTD
PMID:17183730
NCBI chr10:106,717,340...106,874,126
Ensembl chr10:106,717,367...106,874,122
G
Tbrg1
transforming growth factor beta regulator 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TBRG1 mRNA
CTD
PMID:17183730
NCBI chr 8:37,355,274...37,362,933
Ensembl chr 8:37,354,658...37,362,930
G
Tbx18
T-box transcription factor 18
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TBX18 mRNA
CTD
PMID:17183730
NCBI chr 8:88,652,054...88,680,081
Ensembl chr 8:88,652,054...88,680,058
G
Tcerg1
transcription elongation regulator 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TCERG1 mRNA
CTD
PMID:17183730
NCBI chr18:34,505,708...34,566,470
Ensembl chr18:34,505,751...34,566,470
G
Tcf12
transcription factor 12
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TCF12 mRNA
CTD
PMID:17183730
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
G
Tec
tec protein tyrosine kinase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TEC mRNA
CTD
PMID:17183730
NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557
G
Tent5a
terminal nucleotidyltransferase 5A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TENT5A mRNA
CTD
PMID:17183730
NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045
G
Tfcp2
transcription factor CP2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TFCP2 mRNA
CTD
PMID:17183730
NCBI chr 7:131,616,777...131,658,995
Ensembl chr 7:131,616,785...131,658,939
G
Tfdp1
transcription factor Dp-1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TFDP1 mRNA
CTD
PMID:17183730
NCBI chr16:76,162,040...76,200,871
Ensembl chr16:76,162,043...76,200,817
G
Tff2
trefoil factor 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TFF2 mRNA
CTD
PMID:17183730
NCBI chr20:9,215,750...9,219,619
Ensembl chr20:9,215,761...9,219,619
G
Tgif2
TGFB-induced factor homeobox 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TGIF2 mRNA
CTD
PMID:17183730
NCBI chr 3:145,333,152...145,348,599
Ensembl chr 3:145,333,418...145,348,596
G
Thbd
thrombomodulin
multiple interactions
EXP
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein]
CTD
PMID:16778335
NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193
G
Them6
thioesterase superfamily member 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of THEM6 mRNA
CTD
PMID:17183730
NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746
G
Thrap3
thyroid hormone receptor associated protein 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of THRAP3 mRNA
CTD
PMID:17183730
NCBI chr 5:138,445,284...138,487,544
Ensembl chr 5:138,445,295...138,487,477
G
Thy1
Thy-1 cell surface antigen
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of THY1 mRNA
CTD
PMID:17183730
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
G
Timm13
translocase of inner mitochondrial membrane 13
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM13 mRNA
CTD
PMID:17183730
NCBI chr 7:8,809,069...8,810,172
Ensembl chr 7:8,809,058...8,809,910
G
Timm50
translocase of inner mitochondrial membrane 50
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM50 mRNA
CTD
PMID:17183730
NCBI chr 1:83,574,872...83,582,748
Ensembl chr 1:83,556,757...83,582,793
G
Timm8b
translocase of inner mitochondrial membrane 8 homolog B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM8B mRNA
CTD
PMID:17183730
NCBI chr 8:50,954,350...50,955,730
Ensembl chr 8:50,954,342...50,955,729
G
Timp1
TIMP metallopeptidase inhibitor 1
decreases expression
EXP
hydralazine decreases expression of Timp1 protein in blood serum
RGD
PMID:33315911
RGD:407420266
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
G
Timp2
TIMP metallopeptidase inhibitor 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMP2 mRNA
CTD
PMID:17183730
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
G
Tiprl
TOR signaling pathway regulator
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIPRL mRNA
CTD
PMID:17183730
NCBI chr13:77,527,176...77,552,026
Ensembl chr13:77,527,176...77,552,074
G
Tle5
TLE family member 5, transcriptional modulator
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TLE5 mRNA
CTD
PMID:17183730
NCBI chr 7:8,143,357...8,150,295
Ensembl chr 7:8,143,357...8,150,113
G
Tm7sf3
transmembrane 7 superfamily member 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TM7SF3 mRNA
CTD
PMID:17183730
NCBI chr 4:179,518,127...179,550,154
Ensembl chr 4:179,518,130...179,550,154
G
Tma7
translation machinery associated 7 homolog
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMA7 mRNA
CTD
PMID:17183730
NCBI chr 8:109,726,213...109,730,902
Ensembl chr 8:109,726,196...109,735,474
G
Tmco1
transmembrane and coiled-coil domains 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMCO1 mRNA
CTD
PMID:17183730
NCBI chr13:79,460,229...79,483,557
Ensembl chr13:79,460,135...79,483,555
G
Tmed3
transmembrane p24 trafficking protein 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMED3 mRNA
CTD
PMID:17183730
NCBI chr 8:90,241,516...90,249,429
Ensembl chr 8:90,241,516...90,249,346
G
Tmem248
transmembrane protein 248
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM248 mRNA
CTD
PMID:17183730
NCBI chr12:26,430,775...26,457,105
Ensembl chr12:26,432,953...26,457,105
G
Tmem260
transmembrane protein 260
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM260 mRNA
CTD
PMID:17183730
NCBI chr15:21,734,119...21,804,049
Ensembl chr15:21,734,151...21,806,801
G
Tmem80
transmembrane protein 80
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM80 mRNA
CTD
PMID:17183730
NCBI chr 1:196,435,999...196,444,368
Ensembl chr 1:196,436,003...196,444,367 Ensembl chr 1:196,436,003...196,444,367
G
Tmem9
transmembrane protein 9
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM9 mRNA
CTD
PMID:17183730
NCBI chr13:47,458,486...47,475,832
Ensembl chr13:47,458,498...47,475,832
G
Tmsb10
thymosin, beta 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMSB10 mRNA
CTD
PMID:17183730
NCBI chr 4:105,009,959...105,011,095
Ensembl chr 4:105,009,212...105,011,028
G
Tnf
tumor necrosis factor
decreases secretion increases expression multiple interactions
ISO EXP
Hydralazine results in decreased secretion of TNF protein Hydralazine results in increased expression of TNF mRNA Vehicle Emissions inhibits the reaction [Hydralazine results in increased expression of TNF mRNA]
CTD
PMID:16612254 PMID:23415681
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tnfaip8
TNF alpha induced protein 8
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TNFAIP8 mRNA
CTD
PMID:17183730
NCBI chr18:43,183,854...43,299,512
Ensembl chr18:43,183,916...43,299,517
G
Tomm20
translocase of outer mitochondrial membrane 20
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TOMM20 mRNA
CTD
PMID:17183730
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
G
Tomm7
translocase of outer mitochondrial membrane 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TOMM7 mRNA
CTD
PMID:17183730
NCBI chr 4:11,305,122...11,311,963
Ensembl chr 4:11,305,110...11,311,962
G
Topbp1
DNA topoisomerase II binding protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of TOPBP1 mRNA
CTD
PMID:17183730
NCBI chr 8:103,887,805...103,931,662
Ensembl chr 8:103,887,865...103,931,674
G
Tp53
tumor protein p53
multiple interactions increases activity
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TP53 mRNA Hydralazine results in increased activity of TP53 protein
CTD
PMID:12082016 PMID:17183730
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tpi1
triosephosphate isomerase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TPI1 mRNA
CTD
PMID:17183730
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
G
Tpm2
tropomyosin 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TPM2 mRNA
CTD
PMID:17183730
NCBI chr 5:57,770,919...57,780,278
Ensembl chr 5:57,770,864...57,779,992
G
Tpsab1
tryptase alpha/beta 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TPSAB1 mRNA
CTD
PMID:17183730
NCBI chr10:14,360,396...14,362,811
Ensembl chr10:14,360,396...14,362,811
G
Tpte2
transmembrane phosphoinositide 3-phosphatase and tensin homolog 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TPTE2 mRNA
CTD
PMID:17183730
NCBI chr16:69,658,874...69,756,571
Ensembl chr16:69,658,875...69,752,949
G
Traf2
Tnf receptor-associated factor 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAF2 mRNA
CTD
PMID:17183730
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
G
Trappc4
trafficking protein particle complex subunit 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAPPC4 mRNA
CTD
PMID:17183730
NCBI chr 8:44,729,458...44,733,285
Ensembl chr 8:44,725,331...44,733,491
G
Trappc6a
trafficking protein particle complex subunit 6A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAPPC6A mRNA
CTD
PMID:17183730
NCBI chr 1:79,158,587...79,165,502
Ensembl chr 1:79,158,529...79,165,493
G
Trib2
tribbles pseudokinase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIB2 mRNA
CTD
PMID:17183730
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
G
Trim46
tripartite motif-containing 46
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIM46 mRNA
CTD
PMID:17183730
NCBI chr 2:174,641,494...174,654,237
Ensembl chr 2:174,641,496...174,654,141
G
Trip10
thyroid hormone receptor interactor 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIP10 mRNA
CTD
PMID:17183730
NCBI chr 9:2,133,085...2,147,795
Ensembl chr 9:2,133,671...2,147,799
G
Trip6
thyroid hormone receptor interactor 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIP6 mRNA
CTD
PMID:17183730
NCBI chr12:19,386,212...19,390,619
Ensembl chr12:19,386,014...19,390,618
G
Trpt1
tRNA phosphotransferase 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRPT1 mRNA
CTD
PMID:17183730
NCBI chr 1:204,186,295...204,191,294
Ensembl chr 1:204,186,295...204,191,294
G
Tsen54
tRNA splicing endonuclease subunit 54
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TSEN54 mRNA
CTD
PMID:17183730
NCBI chr10:101,041,607...101,050,088
Ensembl chr10:101,042,503...101,050,087
G
Tspan10
tetraspanin 10
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPAN10 mRNA
CTD
PMID:17183730
NCBI chr10:105,715,803...105,721,503
Ensembl chr10:105,715,961...105,719,813
G
Tspan18
tetraspanin 18
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPAN18 mRNA
CTD
PMID:17183730
NCBI chr 3:79,160,060...79,299,907
Ensembl chr 3:79,161,662...79,299,852
G
Tspo
translocator protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPO mRNA
CTD
PMID:17183730
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
G
Tst
thiosulfate sulfurtransferase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TST mRNA
CTD
PMID:17183730
NCBI chr 7:109,948,061...109,955,378
Ensembl chr 7:109,948,062...109,957,216
G
Tubb6
tubulin, beta 6 class V
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TUBB6 mRNA
CTD
PMID:17183730
NCBI chr18:60,943,394...60,953,031
Ensembl chr18:60,943,375...60,954,418
G
Tyw3
tRNA-yW synthesizing protein 3 homolog
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of TYW3 mRNA
CTD
PMID:17183730
NCBI chr 2:243,529,912...243,552,043
Ensembl chr 2:243,529,946...243,552,039
G
Uba52
ubiquitin A-52 residue ribosomal protein fusion product 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UBA52 mRNA
CTD
PMID:17183730
NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807
G
Ube2l6
ubiquitin-conjugating enzyme E2L 6
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UBE2L6 mRNA
CTD
PMID:17183730
NCBI chr 3:69,873,025...69,888,042
Ensembl chr 3:69,873,424...69,888,048
G
Ubox5
U-box domain containing 5
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of UBOX5 mRNA
CTD
PMID:17183730
NCBI chr 3:117,806,212...117,847,711
Ensembl chr 3:117,807,092...117,847,722
G
Ubxn11
UBX domain protein 11
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UBXN11 mRNA
CTD
PMID:17183730
NCBI chr 5:146,329,666...146,353,529
Ensembl chr 5:146,329,842...146,353,526
G
Ubxn4
UBX domain protein 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UBXD2 mRNA
CTD
PMID:17183730
NCBI chr13:39,740,064...39,772,493
Ensembl chr13:39,740,107...39,772,491
G
Uggt2
UDP-glucose glycoprotein glucosyltransferase 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UGGT2 mRNA
CTD
PMID:17183730
NCBI chr15:96,074,557...96,239,365
Ensembl chr15:96,074,564...96,237,806
G
Ulbp1
UL16 binding protein 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ULBP1 mRNA
CTD
PMID:17183730
NCBI chr 1:1,694,255...1,716,160
G
Unc45a
unc-45 myosin chaperone A
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UNC45A mRNA
CTD
PMID:17183730
NCBI chr 1:134,281,930...134,296,661
Ensembl chr 1:134,281,933...134,301,586
G
Uqcc2
ubiquinol-cytochrome c reductase complex assembly factor 2
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UQCC2 mRNA
CTD
PMID:17183730
NCBI chr20:5,202,837...5,214,541
Ensembl chr20:5,202,837...5,214,164
G
Uqcrb
ubiquinol-cytochrome c reductase binding protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UQCRB mRNA
CTD
PMID:17183730
NCBI chr 7:63,814,784...63,820,150
Ensembl chr 7:63,814,797...63,820,150
G
Uqcrq
ubiquinol-cytochrome c reductase, complex III subunit VII
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of UQCRQ mRNA
CTD
PMID:17183730
NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169
G
Usf3
upstream transcription factor family member 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of USF3 mRNA
CTD
PMID:17183730
NCBI chr11:56,470,738...56,529,736
Ensembl chr11:56,476,122...56,529,884
G
Usp33
ubiquitin specific peptidase 33
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of USP33 mRNA
CTD
PMID:17183730
NCBI chr 2:241,283,209...241,328,479
Ensembl chr 2:241,292,985...241,328,479
G
Usp40
ubiquitin specific peptidase 40
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of USP40 mRNA
CTD
PMID:17183730
NCBI chr 9:88,607,920...88,678,940
Ensembl chr 9:88,607,930...88,678,914
G
Usp49
ubiquitin specific peptidase 49
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of USP49 mRNA
CTD
PMID:17183730
NCBI chr 9:13,305,640...13,366,132
Ensembl chr 9:13,308,178...13,366,132
G
Vegfb
vascular endothelial growth factor B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of VEGFB mRNA
CTD
PMID:17183730
NCBI chr 1:204,172,297...204,178,046
Ensembl chr 1:204,172,225...204,177,944
G
Wbp2nl
WBP2 N-terminal like
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of WBP2NL mRNA
CTD
PMID:17183730
NCBI chr 7:113,814,793...113,831,974
Ensembl chr 7:113,814,992...113,831,333
G
Wbp4
WW domain binding protein 4
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of WBP4 mRNA
CTD
PMID:17183730
NCBI chr15:54,862,700...54,890,668
Ensembl chr15:54,862,843...54,890,647
G
Wdr46
WD repeat domain 46
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of WDR46 mRNA
CTD
PMID:17183730
NCBI chr20:4,937,845...4,945,796
Ensembl chr20:4,937,847...4,946,535
G
Wnt1
Wnt family member 1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of WNT1 mRNA
CTD
PMID:17183730
NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651
G
Xylb
xylulokinase
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of XYLB mRNA
CTD
PMID:17183730
NCBI chr 8:119,093,466...119,128,858
Ensembl chr 8:119,096,029...119,128,848
G
Ythdf1
YTH N6-methyladenosine RNA binding protein F1
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of YTHDF1 mRNA
CTD
PMID:17183730
NCBI chr 3:168,024,660...168,040,172
Ensembl chr 3:168,024,663...168,040,172
G
Ywhaq
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of YWHAQ mRNA
CTD
PMID:17183730
NCBI chr 6:40,935,714...40,966,240
Ensembl chr 6:40,935,949...40,966,273
G
Zc3h3
zinc finger CCCH type containing 3
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZC3H3 mRNA
CTD
PMID:17183730
NCBI chr 7:107,440,694...107,525,451
Ensembl chr 7:107,440,694...107,525,451
G
Zdhhc17
zinc finger DHHC-type palmitoyltransferase 17
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZDHHC17 mRNA
CTD
PMID:17183730
NCBI chr 7:46,369,963...46,433,691
Ensembl chr 7:46,369,988...46,433,764
G
Zdhhc7
zinc finger DHHC-type palmitoyltransferase 7
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZDHHC7 mRNA
CTD
PMID:17183730
NCBI chr19:48,139,309...48,156,673
Ensembl chr19:48,139,527...48,156,673
G
Zfand2b
zinc finger AN1-type containing 2B
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZFAND2B mRNA
CTD
PMID:17183730
NCBI chr 9:76,665,466...76,668,447
Ensembl chr 9:76,665,546...76,668,445
G
Zfp18
zinc finger protein 18
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ZNF18 mRNA
CTD
PMID:17183730
NCBI chr10:50,473,428...50,495,707
Ensembl chr10:50,473,483...50,495,706
G
Zfp354c
zinc finger protein 354C
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF354C mRNA
CTD
PMID:17183730
NCBI chr10:35,129,720...35,145,717
Ensembl chr10:35,132,959...35,145,661
G
Zfp386
zinc finger protein 386 (Kruppel-like)
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF519 mRNA
CTD
PMID:17183730
NCBI chr 6:136,966,547...136,984,013
Ensembl chr 6:136,966,586...136,983,441
G
Zfp398
zinc finger protein 398
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF398 mRNA
CTD
PMID:17183730
NCBI chr 4:76,849,672...76,881,075
Ensembl chr 4:76,849,681...76,876,243
G
Zfp592
zinc finger protein 592
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF592 mRNA
CTD
PMID:17183730
NCBI chr 1:134,951,286...135,002,443
Ensembl chr 1:134,967,783...135,002,443
G
Zfp62
zinc finger protein 62
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZFP62 mRNA
CTD
PMID:17183730
NCBI chr10:33,522,618...33,539,446
Ensembl chr10:33,500,323...33,542,013
G
Zfp622
zinc finger protein 622
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF622 mRNA
CTD
PMID:17183730
NCBI chr 2:76,479,605...76,494,405
Ensembl chr 2:76,335,609...76,493,898
G
Zfp768
zinc finger protein 768
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF768 mRNA
CTD
PMID:17183730
NCBI chr 1:181,966,314...181,968,950
Ensembl chr 1:181,966,316...181,969,147
G
Zfp873
zinc finger protein 873
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF441 mRNA
CTD
PMID:17183730
NCBI chr 7:7,926,951...7,959,822
Ensembl chr 7:7,926,957...7,951,803 Ensembl chr 7:7,926,957...7,951,803
G
Zfp94
zinc finger protein 94
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZNF45 mRNA
CTD
PMID:17183730
NCBI chr 1:79,858,188...79,879,702
Ensembl chr 1:79,859,180...79,879,612
G
Zfr
zinc finger RNA binding protein
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZFR mRNA
CTD
PMID:17183730
NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:61,137,611...61,200,322
G
Zmpste24
zinc metallopeptidase STE24
multiple interactions
ISO
[Hydralazine co-treated with Valproic Acid] results in increased expression of ZMPSTE24 mRNA
CTD
PMID:17183730
NCBI chr 5:134,627,218...134,660,360
Ensembl chr 5:134,627,229...134,660,110
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all